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Abstract 
Background: Triathletes, in particular Ironman triathletes, undergo intense 
training and compete in a very physically demanding race. Medical conditions 
in the pre-race period in these triathletes have not been well documented, but 
there is evidence form other endurance sports that symptoms of respiratory 
tract infection are particularly common. However, the prevalence, causes and 
consequences of these symptoms have not been studied in Ironman 
triathletes 
Objective: The aims of this study were: 1) to determine the incidence of 
respiratory tract symptoms (RTS) in triathletes preparing for an Ironman 
Triathlon, 2) to establish the factors associated with the development of these 
RTS, and 3) to determine the effects of the RTS on pre-race training and race 
performance. 
Methods: In this cross-sectional descriptive study, 304 triathletes entering the 
2006 Ironman triathlon in South Africa were recruited as subjects. All the 
subjects completed a validated questionnaire in the 1-3 days before the race 
(during registration). The questionnaire contained sections on demographics, 
training and previous competitions, common general medical conditions that 
they may have experienced, and a detailed section pertaining to RTS and 
allergies, including use of medication. Data on race performance was 
collected after completion of the race. Subjects were divided into the following 
groups, based on their self-reported history of RTS in the 6 weeks period prior 
to the race: no RTS, all RTS, only upper respiratory tract symptoms (URTS), 
lower respiratory tract and/or systemic symptoms (LRT +SS). 
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Results: The main findings in this study were that, 1) 49% of the Ironman 
triathletes reported RTS in the 6-week period before competition, 2) there was 
a strong association between self reported RTS in lronman triathletes and a 
history of self reported allergies rather than training volume (in the 15 weeks 
before the race), 3) self-reported LRT +SS but not URTS in triathletes were 
associated with decreased training in the 6 weeks before the race, 4) self-
reported LRT +SS but not URTS in triathletes resulted in reduced pre-race 
training, predicted race performance, and actual race performance, and 5) 
there was no specific self-reported allergy that is associated with all RTS, 
URTS or LRT +SS in Ironman triathletes. Other findings of the study were that 
medical conditions other than RTS were also commonly reported by triathletes 
while preparing for an lronman competition. Muscle cramping (52%), gastro-
intestinal symptoms (44%), history of sunburn (40%), a history of 
tendon/ligament injuries (38%), allergies (36%) and genital injuries (24%) 
were the most common other reported medical problems in this group of 
triathletes. 
Conclusion: Triathletes, in preparation for a race, report a high frequency of 
medical conditions. RTS are particularly common, and appear to be related to 
allergies rather than other factors including training volume or the calibre of 
the athlete. If RTS are accompanied by LRT or systemic symptoms, they 
decrease training and negatively affect performance on race day. 
Keywords: respiratory tract symptoms, upper respiratory tract infections, 
triathletes, infections, allergies 
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Chapter 1 
Introduction and scope of the thesis 
The Ironman competition is an ultra-distance triathlon consisting of a 3.8 km 
swim, a 180 km cycle and a 42.2 km run. This event is held annually in South 
Aflica during autumn at a coastal town, and attracts over 1000 local and 
international competitors. Following months of intensive training in three 
disciplines, the swim leg starts at 6 o'clock in the morning on race day. The 
fastest triathletes complete the race in about 8-9 hours. The race officially 
closes after 18 hours. 
The Ironman triathlon is clearly a very long, intense and therefore physically 
demanding event. Prolonged intensive training in the weeks before the race, 
as well as the substantial physical challenges on race day are factors that can 
negatively affect the health of the triathletes 1. Triathlete competitions can 
range in duration from 30 min to 36 hours of continuous exercise. Medical 
complications in Ironman triathletes can occur during the preparation phase, 
on race day, and in days to weeks after the event. The possible medical 
problems suffered by Ironman triathletes can affect many systems including 
the metabolic, cardiovascular, neuro-endocrine, gastrointestinal, 
musculoskeletal, uro-genital, and dermatological systems. 
In this thesis, the focus will be on the respiratory system, in particular 
symptoms of respiratory tract infections, which can be affected by intense 
training and competition. The terminology that is used to describe symptoms 
of respiratory tract infections in ultra-endurance athletes varies in the 
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literature, and will be reviewed in Chapter 2 (Section 2.3.1.). However, for the 
purposes of this introduction, symptoms of infection of the respiratory tract will 
be referred to as RTS, symptoms of infection of the upper airways and nasal 
mucosa, will be referred to as upper respiratory tract symptoms (URTS), 
symptoms of infection of the lower respiratory tract will be referred to as LRT, 
and systemic symptoms that can accompany respiratory tract infections will 
be referred to as systemic symptoms (SS). 
To date, the main focus of research, linking mainly URTS to athletes 
participating in ultra-endurance events, has been to study the risk of 
developing these symptoms in the few days or weeks following a competition 
1-3. The incidence, factors associated with RTI symptoms, and the possible 
negative consequences of RTI symptoms in the final 6-8 weeks of training 
before ultra-endurance events has not been well studied. Furthermore, these 
studies have only been conducted in ultra-distance runners, and not in 
triathletes. 
Therefore the work presented in this thesis will focus on the rate of occurrence 
of medical complications, specifically RTS and systemic symptoms, suffered 
by triathletes in the preparatory phase for an lronman competition. In this 
thesis 1) the occurrence of RTS in the 6 weeks before an Ironman triathlon, 2) 
factors that are associated with the development of these RTS, and 3) 
whether RTS that occur in triathletes during this period affect their training and 
performance on race day will be explored. 
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In Chapter 2 of this thesis, aspects related to the development of RTS in 
endurance athlete will be reviewed. In particular, the following will be 
discussed: medical conditions in endurance athletes in general, terminology 
and definitions related to RTS in endurance athletes, and the epidemiology, 
aetiology and consequences of RTS in endurance athletes. 
In Chapter 3 the details of the research study methodology, results and 
discussion of the findings will be presented. In Chapter 4 the main findings of 
this thesis will be summarized. Practical clinical guidelines to sports 
physicians and triathletes on the prevention and management of these 
symptoms will be presented. 
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Chapter 2 
Symptoms of respiratory tract infections (RTI) in 
Ironman triathletes: A review of causes and 
consequences 
2.1. Introduction 
It is well established that regular exercise training is beneficial in the primary 
and secondary prevention of chronic diseases of lifestyle 4-6 including. obesity 
7, hypertension 8;9, coronary artery disease 10, cardiac failure 11;12, 
cerebrovascular disease 13, diabetes mellitus 14, peripheral vascular disease 
15, osteopaenia, and some cancers 16;17. There is thus a perception that 
athletes are generally healthy individuals, and that exercise training also 
protects against the risk of acquiring other acute medical illnesses such as 
infections 18;19, However, there is also epidemiological evidence showing that 
increased exercise training (volume and intenSity), particularly in endurance 
athletes, can be associated with an increased risk of developing infections 20-
25 
Triathletes participate in three endurance sports - swimming, cycling and 
running. Furthermore, Ironman triathletes participate in a particularly 
strenuous ultra-endurance triathlon consisting of a 3.8 km swim, 180 km 
cycle, and a 42.2 km running event. lronman triathletes therefore undergo a 
particularly intense and prolonged periods of training which peak in the 10-12 
12 
weeks prior to a competition. These triathletes are also exposed to a very 
intense and prolonged physical challenge on race day. 
Medical conditions that can occur in triathletes have been studied, but it is 
interesting to note that the majority of studies have focused on medical 
complications that may occur during the event (on race day), or in the 1-3 
week period following race day 1;26-29. It appears that the medical conditions in 
triathletes that may occur during the period of intense training prior to a race 
have largely been ignored. This is in spite of the fact that this is the period 
when the intense and prolonged training may result in medical conditions for 
which a sports physician looking after triathletes is frequently consulted. It is 
for this reason that this thesis will focus on medical conditions that may occur 
in triathletes, specifically those conditions that may affect triathletes in the 
weeks as they prepare for competition. 
There is some evidence to suggest that one of the most common medical 
conditions that endurance athletes experience during this period are 
respiratory tract symptoms ranging from those in the upper airways ('runny 
nose', blocked' nose, sore throat) to the lower respiratory tract (cough, 
wheeze, chest pain). These symptoms may also be accompanied by systemic 
symptoms such as fever, muscle aches, joint pain, and fatigue. Although 
these symptoms have been mostly attributed to an infection in the respiratory 
tract, the precise aetiology of these symptoms, whether they are indeed of 
infective nature. and their possible effect on training and competition is not 
well established. A better understanding of the cause of these symptoms 
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during this period will ultimately result in better clinical advice to triathletes 
preparing and competing in the Ironman triathlon. 
This review will focus on respiratory tract symptoms (RTS) in triathletes and is 
divided into the following sections. In Section 2.2., medical conditions that can 
occur in endurance athletes, particularly triathletes, will be reviewed briefly. 
The terminology and the epidemiology of RTS in endurance athletes will be 
discussed in Section 2.3., while the current hypotheses to explain the 
aetiology of RTS in endurance athletes will be reviewed in Section 2.4. 
Current knowledge on the effects of RTS on training and performance 
(Section 2.5.), as well as current clinical guidelines for the management of 
athletes presenting with RTS (Section 2.6.) will also be reviewed. 
2.2. Medical conditions in endurance athletes - with specific 
reference to triathletes 
Medical conditions associated with endurance exercise can affect many organ 
systems, including the cardiovascular, dermatological, neuroendocrine, 
musculoskeletal, genitourinary, gastro-intestinal, metabolic, central and 
peripheral nervous systems 1:26-29. Of particular interest in this thesis are the 
medical conditions in triathletes that affect the respiratory system, and more 
specifically RTS. Medical conditions in triathletes can occur at various stages 
of training and racing. These stages can be divided into the pre-race period 
(during the preparation training period), during the race (intra-competition), or 
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the post-race period recovery period (from immediately after the finish up to 2-
6 weeks later). 
2.2.1. Pre-race medical conditions in triathletes 
Medical conditions that occur during this period of intense training in 
preparation for an event have not been well studied in triathletes and in other 
endurance sports such as running. Most of the studies that have examined 
medical conditions during endurance competitions such as marathon and 
triathlon, do not mention the pre-race medical status of the athletes. The 
prevalence of pre-race symptoms of medical conditions has often not been 
reported 1 ;2;28. 
2.2.2. Medical conditions that occur in triathletes during racing 
Medical conditions that can occur in triathletes during racing have recently 
been reviewed 1. The following medical complications can occur in triathletes 
during competition: exhaustion, dehydration, muscle cramping, hypothermia, 
heat stroke, hyponatraemia, postural hypotension, excessive exposure to 
ultraviolet radiation, musculoskeletal injuries and minor trauma, infections, 
gastrointestinal tract problems, immunosuppression, sympathetic nervous 
system exhaustion and haemolysis 1;26. An analysis of clinical records from 
the 1984 and 1985 lronman races showed that the most common medical 
condition during racing is dehydration, accounting for 45% of the treatments in 
the medical care facility. Other commonly occurring problems were muscle 
cramps, exhaustion and musculoskeletal injuries. The risk of developing 
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medical conditions during racing increases with the duration of the race. It has 
been reported that there is a ten-fold increase in the risk of medical conditions 
in a 13-hour triathlon relative to a 3-hour triathlon 26. Medical conditions in 
triathletes also occu r mostly towards the end of the race 30, and in the 
Honolulu Triathlon between 1981-1984,75% of medical visits occurred after 9 
hours into the race with exhaustion, dehydration and heat injury being 
particularly common. Other common medical conditions in triathletes during 
the race were abdominal cramps with or without diarrhoea and muscular 
cramps 1;31;32. 
2.2.3. Medical conditions that occur in triathletes during the recovery (2-
6 weeks) following competition 
Many medical conditions that present during a race may well persist for a few 
days into the recovery period. The most commonly reported post-race medical 
condition following endurance events is the presence of upper respiratory tract 
symptoms (URTS) in the first 10-14 days following intense competition. Post-
race URTS have been mostly reported following endurance running events 
2;3;33, but have not been well studied in triathletes. 
It is generally accepted that these post-race URTS occu r as a result of 
immunosupression following the high intensity and prolonged exercise 
associated with triathlon competitions 34-36. Furthermore, it is generally 
assumed that these symptoms have an infective origin 3;20;21. However, the 
'infective' hypothesis for RTS has not been proven 37, and this will be 
reviewed in more detail (Section 2.4.). 
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2.3. Respiratory tract symptoms (RTS) in endurance athletes· 
with specific reference to triathletes 
2.3.1. Terminology and definitions 
As mentioned, endurance athletes can present with RTS ranging from 
'blocked' nose, 'runny nose', sore throat, swollen glands, cough, wheeze, and 
chest pain. These symptoms may be accompanied by additional systemic 
symptoms such as fever, headache, muscle aches, joint pains and general 
fatigue. In some instance the term 'flu-like' illness has been used for the RTS, 
which are accompanied by systemic symptoms. In most studies where these 
RTS, or more specifically URTS, have been docLimented, these were self-
reported by athletes, without any evidence of actual infection 37. We are aware 
of only one study in which attempts have been made to obtain actual evidence 
of an infective agent by using bacterial and viral cultures to identify an 
infective agent 38 in distance runners presenting with post-race URTS. 
Therefore, the general use of the term Upper Respiratory Tract Infections 
(URTI), as has been used in many reports, without documenting actual 
evidence that these symptoms are due to an infection, may well be incorrect. 
At present, it is well recognized that an athlete presenting with RTS that are 
localized to the upper airways (nose and orophraynx) is given different 
medical advice about exercise and training, when compared with an athlete 
presenting with RTS below the orophraynx (cough, wheeze, chest pain), or 
athletes presenting with accompanying systemic symptoms, such as fever, 
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muscle aches, joint pains, and general fatigue 21. This clinical test has also 
referred to as the 'neck check' 39-41. The use of the terms Upper Respiratory 
Tract Symptoms (URTS) ('blocked' nose, 'runny nose', sore throat, swollen 
glands), Lower Respiratory Tract Symptoms (LRTS) (cough, wheeze, chest 
pain) and systemic symptoms (fever, muscle aches, joint pains, general 
fatigue) to describe these clinical presentations is therefore more appropriate. 
For the purposes of this thesis, the following terminology will be used: 
• Upper Respiratory Tract symptoms (URTS) will refer to the presence of 
respiratory symptoms that are localized to the nose and pharynx ('blocked' 
nose, 'runny nose', sore throat) 
• Lower Respiratory Tract (LRT) symptoms will refer to the presence of 
respiratory symptoms below the level of the pharynx (cough, wheeze, 
chest pain) 
• Systemic symptoms (SS) symptoms of infection will refer to symptoms 
such as fever, muscle aches, joint pain, and general fatigue that may 
accompany infections 
It should be pointed out that we are fully aware of the fact that RTS in athletes 
could also be due to many other cardiorespiratory conditions. In particular, we 
recognize that asthma is a very common respiratory condition in athletes that 
could give rise to RTS. However, in this thesis we wish to confine the 
discussions to RTS that have been related to infections, and the main focus is 
on URTS. We also acknowledge that systemic symptoms that are listed above 
can also occur as a result of many other infections (not only those affecting 
the respiratory tract) and other systemic conditions. Clinical decisions advising 
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athletes presenting with RTS are often made by distinguishing between URTS 
(above the neck) and either LRTS and/or SS (below the neck). This aspect 
will be discussed further in Section 2.6. 
2.3.2. Epidemiology of RTS in endurance athletes 
Respiratory tract infections (RTI), in particular URTI, are very common in the 
general population 42, and are more likely to affect individuals in the extremes 
of age and the immune-compromised individual 43, It has been reported that 
75-80% of all acute morbidities in the population of the United States of 
America are due to respiratory disease, 80% of which are due to viral 
infections of the respiratory tract, with an average of 3-6 respiratory tract 
illnesses per person per year 42;44, URTI is the most common type of infection, 
and is mainly caused by viruses 42. 
In athletes it has also been reported that upper respiratory infections 
(commonly caused by viruses) are by far the leading cause of infectious 
diseases in the training room 42. A number of studies have documented 
URTS in endurance athletes, including runners 2;3:45-47, cross-country skiers 48, 
swimmers 49;50, rowers 51, and in other sports, such as tennis players 52, 
gymnastics 53, and even during military training 54. It is very important to note 
that in all these studies. there is no verification that the symptoms are due to 
an infection. Hence, in all these studies it is correct to describe these as 
symptoms of URTI rather that actual documented URTI. The use of the 
terminology URTS, will therefore be used consistently in this thesis, when 
referring to these studies. 
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The risk of developing URTS in athletes has recently been reviewed 20. In one 
of the first studies to document the relationship between URTS and 
endurance exercise, Peters and Bateman (1983) found that the incidence of 
URTS was twice as high in ultra-distance runners in the first 10-14 days 
following an endurance race, when compared with suitable sedentary controls 
followed up in the same time period 2. These researchers also reported that 
the incidence of URTS was higher among the faster runners. 
Following that first report, there have been at least three retrospective 25;55;56, 
and five prospective 3;33;45;57;58 studies documenting URTS in different groups 
of athletes. An in depth discussion of the findings of all these studies is 
beyond the scope of this review. However a summary of the main findings 
from these studies is as follows: 
• Following endurance events (mainly ultra-marathon running) athletes 
experience an increased incidence of URTS compared with sedentary 
controls 2;3;55 
• Prospective studies and retrospective surveys in endurance athletes over 
months show that increased training is associated with an increased risk of 
URTS 25;45;57 
• Some studies report other factors that increase the risk of athletes to 
develop URTS including female gender 25;45, decreased Vitamin C intake 3, 
perceived stress 25, sleep deprivation 25, and nutritional unawareness 25. 
• In two prospective studies, moderate intensity training resulted in 
increased natural killer cell function, increased T-cell function and reduced 
incidence of URTS 33;58 
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Apart from studies in athletes, there are also epidemiological studies showing 
that moderate intensity recreational or occupational activity is associated with 
a decreased risk of URTS 59, In animal studies, moderate intensity exercise 
has also been associated with a decreased risk of URTI 60, 
Over the past decade, the results of studies in athletes and other populations 
have led to the commonly accepted hypothesis that the relationship between 
exercise training and risk of URTS is a 'J' shaped curve 25;39;61;62, It appears 
that physical inactivity is associated with an increased risk of URTS 63, while 
moderate intensity and duration physical activity has been shown to be 
protective in some 24;64-67, but not in all studies 68;69, However, high-intensity, 
prolonged exercise, such as during endurance training and competition, may 
increase the risk of developing URTS 25;45;57;70. 
It is important to note that the risk of developing URTS has not been studied in 
Ironman triathletes, yet this sport is one of the most physically demanding 
endurance sports. Therefore the focus of the research presented in this thesis 
is on RTS in triathletes. 
In the following section, the possible causes for the RTS in athletes will be 
briefly reviewed. In particular, the different hypotheses for the development of 
these RTS in athletes will be reviewed. 
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2.4. Aetiology and pathophysiology of RTS in endurance 
athletes 
Until recently. it was generally assumed that the RTS in athletes were due to 
an infective cause, and that this increased risk of infection was because 
prolonged intense training or competition has been associated with a 
'suppression' of a variety of parameters in the immune system. The 
'suppression' of immune parameters in the 3-72 hours following intense and 
prolonged training has been termed the 'open window' period. During this 
period, it is hypothesized that infective agents entering the upper respiratory 
tract would cause URTI. Additional factors that may increase the risk of 
infection are the large volumes of air entering the respiratory tract particularly 
when mouth breathing is used by athletes during high intensity exercise 71 and 
nutritional deficiencies in particular carbohydrate 72 and Vitamin C deficiency 
46;47;73-75 
However, it is also well established that RTS are not always due to an 
infection and that there may be other causes for these symptoms such as 
allergies or inflammation caused by other physical or chemical irritants 76. It is 
only more recently that other possible causes of URTS in athletes during 
training or competition have been proposed. The possible hypotheses for the 
cause of RTS in endurance athletes will be discussed under the following 
headings: Infective hypothesis, allergic hypothesis, and other causes. 
Scientific evidence for each of these will now be briefly reviewed. 
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2.4.1. Infective hypothesis for RTS in athletes 
Since 1990, the relationship between an acute exercise bout and immune 
parameters, as well as the relationship between exercise training and 
changes in the immune parameters has received more and more attention. 
Over the past 10-15 years, the number of publications in this field have 
increased by more than 10 fold 77. There is now an extensive body of 
knowledge documenting the relationship between exercise and the immune 
system and this has recently been reviewed in a number of publications 
19;22,37,77;78;79-82. The main focus of the research in this thesis is not on exercise 
immunology, and hence an in-depth review of the interaction between 
exercise and the immune system is beyond the scope of this chapter. 
However, the main current findings relating changes in the immune system as 
a result of exercise, and how these may relate to RTS in athletes will be 
reviewed. 
It is well established that an acute bout of exercise as well as exercise training 
can alter a variety of immune parameters. Changes in systemic immunity 19, 
mucosal immunity, and cytokine 79 in response to exercise have been 
reviewed. To date, there have been numerous studies that were conducted to 
relate these changes in immune parameters to URTS in athletes. However, in 
most of these studies, no direct relationship between changes in immune 
parameters and the presence of URTS could be documented. This lack of 
association between measures in immune function and URTS was first 
pointed out by Shephard in 2000 37, and more recently by Maim in 2004 77, 
and Gleeson et al. 2004 80. The evidence for a direct link between observed 
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changes in immune parameters, and the development of URTS can be 
summarized as follows: 
• An acute bout of exercise as well as regular exercise training can alter 
systemic 22;33;35;51;58;83-87 and mucosal immunity 52-54;59;64;88-95 by enhancing 
some parameters and suppressing others 
• The biological significance of these alterations in the immune system are 
not well established, and will require further investigation 
• The association between changes in immune parameters and the 
development of RTS in athletes has been examined 49;52-54;59;86;89;93;96, but 
to date, no consistent cause-effect relationship has been documented 
• Nutritional interventions to change immune system parameters and 
decrease the risk of URTS in athletes have been studied. 
• Although the effect of nutritional supplements such as carbohydrates 72, 
glutamine 97, and Vitamin C 46;47;73-75 on immune parameters have been 
studied 98-101, with the exception of Vitamin C supplementation 3, none of 
the other supplements have been shown to decrease URTS in athletes 72 
99 
It is therefore clear that the relationship between exercise-induced changes in 
immune parameters and the development of RTS in athletes is not well 
established. Furthermore, there are no studies confirming the diagnosis of an 
infection in athletes presenting with URTS where either serological criteria 
have been used, or where actual pathogens have been cultured. In 
conclusion, scientific evidence supporting the infective hypothesis as the 
cause of URTS in athletes undergoing training or competition is lacking. 
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Alternative hypotheses, perhaps linking changes in the immune system 
parameters during intense exercise, and the development of RTS have to be 
considered. It has been suggested that allergic disorders, which are also 
mediated through the immune system, may account for the development of at 
least some RTS in athletes. This hypothesis will now be explored. 
2.4.2. Allergic hypothesis for RTS in athletes 
It is well established that allergies are very common worldwide and that the 
prevalence of allergies has increased over the decades 102;103. The prevalence 
of allergic diseases in the population of industrialized countries has been 
estimated at 10-25%. As mentioned, allergies have increased significantly 
over the last 50 years in developed countries probably due to air pollution 104. 
There is a very wide spectrum of clinical presentations of allergic conditions, 
ranging from a benign rash to exercise-induced anaphylaxis 105. Allergic 
conditions of the respiratory tract in athletes can vary from allergic sinusitis, 
allergic rhinitis, allergic rhinoconjunctivitis, to allergic asthma 103;106-108. The 
prevalence of asthma amongst elite athletes ranges between 3.7% and 
28.8%, with evidence that this prevalence has almost doubled between 1976 
and 1996. A similar increase in prevalence has been reported for allergic 
rhinitis. The foclJS of this thesis is mainly on URTS; hence allergic asthma in 
athletes will not be discussed further. However, the possibility that URTS in 
athletes may be related to allergies of the upper respiratory tract will be 
explored. 
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It has been suggested that allergic rhinitis 11 and allergic rhinoconjunctivitis 108 
are more common in athletes than currently thought, and these conditions are 
probably under-diagnosed and under-treated in athletes 103, In one study, 
16,8% of Swiss athletes from different sports were reported to suffer from hay 
fever, with 59% of the athletes requiring medication during the pollen season 
to control symptoms 109, In this study, it was also reported that the athletes 
with hay fever also had Significantly more exercise-related RTS, In a study 
among elite athletes preparing for the Olympic Games in 2000, 56% of 
athletes gave a history consistent with allergic rhinoconju nctivitis, 41 % had a 
positive skin test response to anyone allergen and 29% reported seasonal 
allergic conjunctivitis 110, In a retrospective analysis of medical records of the 
1976 and 1980 Australian Olympic teams the prevalence of allergic disorders 
in athletes was reported as 20% iii, 
There also appears to be a difference in the prevalence of allergic conditions 
amongst the different sports with aquatic sports (swimming, rowing and 
diving) with a higher risk of allergic rhinitis than non-aquatic sports, 
Paradoxically, equestrians have the lowest atopic tendencies, probably due to 
natural selection 108, 
The prevalence of allergic conditions in triathletes has to our knowledge not 
been studied. However, the prevalence of allergies, in particular allergic 
rhinitis in endurance athletes, was recently reported in two studies. In one 
study among elite athletes preparing for the Olympic Games, 18.3% of the 
athletes reported allergies, with 14.5% reporting allergic rhinitis. In this study, 
there were no gender differences, but endurance athletes reported a higher 
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prevalence of allergies than other subgroups 112. In a recently published 
survey among 261 male and 185 female athletes participating in different 
sports, the prevalence of a 'disturbing' allergy was 32.1 %, with the highest 
prevalence in endurance sports (43.5% of athletes) 71, This prevalence of 
allergies in athletes was higher than that reported for the normal population 
(20%), Furthermore, 26.5% of all athletes, and 36.1 % of endurance athletes 
reported allergic rhinitis 71, In this survey, the prevalence of all allergies, and 
allergic rhinitis was similar in male and female athletes 71. 
In summary, there is evidence that allergies are common in elite athletes with 
the prevalence of any allergy varying between 16 and 32%. Allergic rhinitis (or 
allergic rhinoconjunctivitis as it is also referred to if conjunctival symptoms 
occur) appears to be one of the most common allergic conditions in athletes 
(26-56% of athletes). Finally, recent data indicates that endurance athletes in 
particular have a high prevalence of allergic conditions in general (32% of 
athletes), and more specifically allergic rhinitis (44% of athletes). 
The clinical presentation of allergic conditions that affect the respiratory tract 
may mimic those of an URTI. Common URTS that could be due to either 
infections or allergies are blocked nose and runny nose, while more systemic 
symptoms. such as headache, malaise and fatigue, can also occur due to 
allergies 103. Associated symptoms, such as itchy nose, sneezing and itchy, 
runny eyes, are more likely due to allergic than infective causes 71;108:113. 
However, chronic allergies can, similar to infections, also result in impaired 
sports performance 103;110 (Section 2.5.2.). 
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It can be therefore be hypothesized that URTS in endurance athletes may be 
related to allergies rather than infective nature, or there may be an interaction 
between these two mechanisms for the following reasons: 
• There is a high prevalence of reported allergies. particularly in endurance 
athletes 
• The most common reported allergy in endurance athletes appears to be 
allergic rhinitis (rhinoconjunctivitis) 
• There is an overlap of symptomatology between allergic rhinitis and URTS 
due to an infective cause 
• Both allergies and infective conditions have an immunological basis, and 
acute exercise, as well as regular training, can result in changes in 
immune parameters 
• The relationship between observed changes in the immune system with 
exercise and the development of allergies has not been systematically 
investigated 103 
• Chronic nasal allergies cause swelling which decreases drainage and can 
predispose to the development of infections 108 
• There may well be a continuum of URT disease with an overlap between 
respiratory tract allergies and infections, which has to date not been 
explored. 
In the research component of this thesis, some aspects of the relationship 
between RTS in triathletes and history of allergies will therefore be 
investigated. 
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2.4.3. Other hypotheses for RTS in athletes (physical factors) 
Any discussion of the possible causes of RTS in athletes will not be complete 
unless it is mentioned that many other irritants can also cause an 
inflammatory response in the respiratory tract. A non-allergic, non-infective 
rhinitis can be caused by physical factors. Physical factors that may cause 
RTS in athletes include high ventilatory rate, cold, dry air, increased air 
turbulence, mouth-breathing, and inhaled irritants (physical. chemical and 
allergens). When the ventilatory rate exceeds 30Umin there is a tendency 
towards both mouth breathing and nasal breathing and this causes deposition 
of airborne allergens and irritants into the upper and lower respiratory tract 71. 
Pollutant irritants are classified as primary or secondary. Primary pollutants 
are directly from the source such as inorganic gases. Secondary pollutants 
result from chemical reactions of emitted and natural precursors. Pollutants of 
major concern to respiratory health are sulphur dioxide (S02), photochemical 
smog (ozone and nitrogen dioxide - N02) and airborne particulates 104. 
Recently, it has been documented that there is an increase in airway 
inflammatory cells, possibly related to increased ventilation of cold and dry air 
114;115. The precise relationship between these observed inflammatory cells 
and respiratory tract pathology in athletes requires further investigation 114. It 
is important to point out that other hypotheses relating physical and chemical 
factors to RTS in athletes may require further study. 
2.4.4. Summary: Hypotheses for RTS in athletes 
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In summary, the precise aetiology and pathogenesis of RTS in athletes during 
training, and immediately after intense competition is not clear. Until recently. 
the prevailing hypothesis for the high incidence of mainly URTS in endurance 
athletes following competition was that alterations in the immune system post-
exercise cause infections. However, actual infection has never been 
documented either clinically, by serological means, or through culture of the 
organisms. Furthermore, despite numerous attempts, no clear relationship 
between altered immune parameters and URTS has been documented. 
Therefore the infective hypothesis for RTS in athletes requires further study, 
or alternative hypotheses have to be considered. 
Concomitantly, it has been documented that respiratory tract allergies, in 
particular allergic rhinitis, is common in athletes, especially in endurance 
athletes. The symptoms of allergic conditions of the URT and the symptoms of 
URTI overlap, and the possibility that RTS in endurance athletes is related to 
allergies has to be considered. Finally, other physical factors causing RTS in 
athletes must not be disregarded. 
2.5. Effects of RTS on training and competition in endurance 
athletes 
The effect of RTS on training and performance has not been well investigated. 
This is probably because the aetiology of RTS in athletes is not established. 
The effects of both RTI and allergic conditions of the respiratory tract on 
training and athletic performance will now be discussed. 
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2.5.1. The effects of RTI in athletes on training and performance 
There are only a few studies where the effects of RTI on training and 
performance have been examined. The main reason for this is that although 
very rare, some infective agents can cause an associated myocarditis 42;116-
118. Viral myocarditis has been the cause of sudden death in athletes 117;118. 
Therefore, the current guidelines for athletes with documented RTS is to avoid 
training if there are any symptoms of possible concomitant myocarditis, such 
as chest pain, shortness of breath at rest, resting tachycardia, or systemic 
symptoms, such as fever, myalgia or joint pain. If any of these symptoms are 
present, athletes are advised not to train at all based on clinical advice 42. For 
obvious ethical reasons the validity of this advice has not been studied 
systematically 21. If symptoms are localized to the URT, athletes frequently do 
not seek medical assistance and, based on anecdotal evidence, many 
continue training. However, the effects of these localized URTS on training 
and performance have not been well investigated. 
The effects of febrile illness on muscle function in humans have been 
investigated in a few studies. In one study where a fever was induced in 7 
volunteers by inoculation with the sandfly fever virus, it was documented that 
there is a transient decrease in muscle function which correlated with myalgia, 
rather than the presence of fever 119. In this study, it was not possible to 
distinguish between inactivity (bed rest) or the febrile illness as the main 
cause of loss of muscle strength. In another study by the same investigators, 
isometric muscle strength and isometric muscle endurance were recorded 
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serially (during fever, after fever, at 1 and 4 months after the infection) at the 
time of an acute infectious disease of viral or mycoplasmal aetiology in over 
30 young men. In this study, the febrile illness resulted in a 5-15% decrease in 
isometric muscle strength and a 13-18% decrease in isometric muscle 
endurance as compared to control subjects undergoing bed rest for the same 
time period as the infected subjects 120;121. It is important to point out that in 
these studies the infection was clearly documented, and that it was associated 
with systemic symptoms (fever). The effects of a localized URTI on exercise 
performance and training has to our knowledge not been studied, other than 
in a report where URTI was the main medical reason for absence from 
training in elite skiers 48. 
Therefore in this thesis the relationship between RTS in triathletes and pre-
competition training, as well as actual performance on race day will be 
explored. Furthermore, a distinction will be made between localized URT 
symptoms, and those accompanied by lower respiratory tract or systemic 
symptoms. 
2.5.2. The effects of allergies in athletes on training and performance 
The potential negative effects of allergies on training and performance in 
athletes have not been well studied. To our knowledge, there are no studies 
that have used established physiological performance variables to measure 
the effects of allergies conditions on exercise performance. There are 
anecdotal reports, which are not confirmed by physiological measures, that 
Olympic athletes with severe exacerbations of allergic conditions have sub-
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optimal exercise performance 110, It is also known that rhinitis often causes 
changes in sleep patterns due to nasal obstruction, rhinorrhoea and sinus 
pressure 113, and the resultant tiredness and fatigue could impair athletic 
performance 71, 
Short bouts of sprinting depend on nasal breathing for optimal performance, 
and nasal obstruction that is associated with allergic rhinitis may inhibit this 
mechanism 71, Allergic rhinitis has also been associated with alterations in the 
central nervous system function, which also may significantly impair athletic 
performance. Reaction time, attention and vigilance were decreased during 
cognitive processing tests, when subjects suffering from allergic rhinitis were 
exposed to pollen 102. 
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2.5.3. Summary: RTS and exercise performance 
The effects of RTS in athletes, whether due to infections or allergies, on their 
exercise performance and training have not been well studied. It appears that 
if an infective episode is accompanied by systemic symptoms, such as fever 
and myalgia, muscle function is impaired for a time period following recovery. 
There are no data to determine the effect of localized URTS on training and 
exercise performance. Allergies could, based on general clinical effects, affect 
training and performance, but this has not been systematically evaluated. 
2.6. Clinical advice to athletes presenting with RTS 
The clinical advice that is currently given to athletes presenting with RTS is 
largely based on whether the RTS are confined to the upper airways (above 
the neck). or whether there are LRT or systemic symptoms (below the neck). 
This clinical test has been termed the 'neck check' 39-42. The main reasons for 
adopting this clinical approach are twofold. Firstly, LRT or systemic symptoms 
may indicate a generalized (systemic) infection, and systemic viral or bacterial 
infections may be associated with myocarditis, and this is a potential cause of 
sudden death in an exercising athlete 42;116;117. Secondly. as has been 
discussed (Section 2.5.1.), there are indications that exercise performance is 
impaired significantly when LRT or systemic symptoms are present. 
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Therefore the current clinical approach when athletes present with RTS is to 
document localized ('runny nose', 'blocked nose', sore throat) or additional 
LRT (cough, chest pain, wheeze) or systemic symptoms (muscle aches, joint 
pain, fever, fatigue). If only localized symptoms are present, moderate 
intensity exercise is allowed for a short duration, and depending on how the 
athlete feels, this can be continued. In the presence of any LRT or systemic 
symptoms exercise is not allowed and follow-up clinical assessment is 
advocated 39-42. 
However, in this current clinical approach, the presence or absence of allergic 
symptoms and their management, which is different to that of URTI 103;108;113, 
is largely ignored. If a closer association between RTS in athletes undergoing 
intense training and allergies is documented, this current clinical approach 
may have to be reconsidered. 
2.7. Summary and conclusions 
• Medical conditions associated with the lronman Triathlon and other ultra-
endurance physical activities are common 
• RTS is one of the more common medical conditions that is encountered in 
endurance athletes, particularly during intense training and immediately 
after races 
• There are many studies documenting alterations in immune parameters in 
athletes undergoing intense training and competition 
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• It is a common assumption that RTS in endurance athletes are as a result 
of infections during periods where there are known alterations in immune 
parameters 
• There are no studies directly linking alterations in immune parameters in 
response to training and documented evidence of infections in athletes 
• Allergic conditions, in particular allergic rhinitis, are common in endurance 
athletes 
• There is some overlap in the symptomatology of URTI and allergic rhinitis 
• Chronic allergic rhinitis may predispose to the development of URT 
infections 
• The infective hypothesis, the allergic hypothesis and alternate hypotheses 
to explain the high prevalence of RTS in endurance athletes require further 
investigation 
• Current clinical guidelines for the management of RTS in athletes are 
mainly based on the assumption that RTS in athletes are only as a result 
of an infective cause 




Respiratory tract symptoms (RTS) in triathletes 
participating in an Ironman Triathlon: An investigation 
of causes and consequences 
3.1. Introduction 
The Ironman Triathlon is an ultra-endurance event comprising of a 3.8 km 
swim, 180 km cycle and a 42.2 km run. lronman triathletes can suffer from a 
variety of pre-race, intra-competition, and post-race medical conditions 1;26-29. 
One of the most common medical complaints in endurance athletes is URTS 
2;3;33, and these occur mostly in the 1-2 weeks after an event. However, URTS 
have also been reported to occur in endurance athletes at times of increased 
training volume and intensity 25;45;57, Therefore RTS, in particular URTS, are 
likely to be common in I ron man triathletes in the 6 weeks before a 
competition, when training volume and intensity is likely to be very high. 
However, the incidence of RTS in triathletes during this time has not been 
investigated. 
The most common hypothesis for the development of URTS in endurance 
athletes during periods of intense training or immediately following competition 
is that immunosupression occurs, resulting in an infection. Although intense 
training has been shown to alter both systemic 22;33;35;51;58;83-87 and mucosal 
immunity 52·54;59;64;88-95 in endurance athletes, an exact cause-effect 
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relationship of these changes to the development of URTI has not been 
documented, despite many attempts 49;52-54;59:86;89;93;96. Furthermore, there is 
no study showing that URTS in endurance athletes is due to an infection, and 
in only one study to date, no positive viral or bacterial cultures could be 
obtained in runners presenting with post-race URTS 38. Therefore the 
'infective' hypothesis for RTS in endurance athletes requires further study, 
and alternative hypotheses may have to be considered. 
There is a growing body of evidence that allergies are common in elite 
athletes, including endurance athletes, and that these are under-recognized 
71;103;108. It has been documented that between 26-56% of athletes suffer from 
allergic rhinitis, and in endurance athletes specifically. the prevalence of 
allergic rhinitis has been reported as 44% 71. Because the symptoms of 
allergic rhinitis overlap with those reported as URTS in endurance athletes, it 
is possible that allergies may accou nt for at least some of the athletes 
presenting with URTS. This 'allergic' hypothesis for RTS in endurance 
athletes requires further investigation. 
The effect of RTS, in particular URTS, in endurance athletes on training and 
performance during races is not well documented. There are studies 
indicating that RTS associated with a febrile illness or myalgia can decrease 
muscle strength and endurance 119-121, However, there is anecdotal evidence 
suggesting that most athletes with localized URTS often continue training. The 
effects of these URTS on training and performance are not documented. 
Clinical advice to athletes presenting with RTS is based to a large extent on a 
distinction between localized URTS (above the neck) and associated lower 
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respiratory tract (LRT) or systemic symptoms (below the neck) - known as the 
'neck check' 39-42. The main reason for this distinction is that LRT and 
systemic symptoms may be associated with viral myocarditis, a condition that 
is very serious and can cause sudden death in athletes 116-118. However, this 
current clinical advice is based on the assumption that RTS in athletes are of 
an infective origin, and this requires further study. 
RTS in elite triathletes, in particular Ironman triathletes, has to date not been 
investigated. The purpose of this investigation is to answer some of the 
questions related to RTS in endurance athletes, and triathletes in particular. 
More specifically, the aims of this study are: 1) to determine the incidence of 
RTS in triathletes preparing for an lronman Triathlon, 2) to establish the 
factors associated with the development of these RTS, and 3) to determine 
the effects of the RTS on pre-race training and race performance. 
3.2. Methods 
3.2.1. Type of study 
Descriptive cross-sectional study. 
3.2.2. Subjects 
All 1136 triathletes (970 male, 85.4% and 166 female, 14.6%) who registered 
for the 2006 "Spec-savers" Port Elizabeth South African Ironman Triathlon 
(3.8 km swim, 180 km cycle and 42.2 km run), which was held during March 
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2006, were considered as potential subjects for this study. In the 2 months 
prior to the event, information about the study was posted on to the official 
race website (Appendix 1). This information included details about the study 
procedures (Appendix 2). the informed consent form (Appendix 3) and copies 
of the questionnaires to be completed (Appendix 4) and a service for 
triathletes to ask questions about the research by telephone or email. Prior to 
the study, the protocol was approved by the Research Ethics Committee of 
the University of Cape Town (REC ref no. 425/2005) (Appendix 5), as well as 
the general organizing committee and the medical sub-committee of the 2006 
"Spec-savers" Port Elizabeth South African Ironman Triathlon. 
Recruitment for the study took place at the registration area in the 3 days prior 
to the event. A research area was established in close proximity to the 
registration desk. As triathletes reported at the registration desk, they were 
informed about the nature of the study, and could then volunteer to take part 
in the study. Triathletes then reported to the research staff, where further 
information was given, and any questions were answered. Once triathletes 
gave informed written consent to be part of the study, they continued with the 
completion of a pre-race questionnaire. Of the 1136 triathletes who registered 
for the event, 992 (87.2%) started the race and 304 (26.8%) triathletes agreed 
to complete the pre-race questionnaire. 
Triathletes were encouraged to complete the questionnaire whilst remaining in 
the research area and the majority complied. Altematively, triathletes were 
allowed to take the questionnaire with them and return it the next day or on 
the morning of the race « 10% of questionnaires were returned this way). 
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3.2.3. Pre-race questionnaire 
For the purposes of this study, a previously validated pre-race questionnaire 
was modified and then used 32 122 31. The content of the medical section of the 
questionnaire was based on common medical problems that were previously 
reported in triathletes 1. The modified questionnaire was further validated by 
testing it on a sample of triathletes that were not part of the research study. 
These triathletes were asked to read the questionnaire and assess its ease of 
administration, relevance and ease of understanding. The athletes then gave 
independent comments which were used to review the format and content of 
the questionnaire. 
The pre-race questionnaire consisted of various sections and included details 
of each triathlete's medical, racing and training history (Appendix 4). The 
information obtained from this questionnaire was used in a number of studies 
that were conducted at this event. In this particular study, information from the 
following sections was used: (1) demographic details (including age, height, 
weight and gender); (2) a history of previous participation in distance running 
(5 km, 10 km, 21.1 km and 42.2 km) and lronman (sprint, standard swim, run, 
cycle, half Ironman, Ironman) events (including personal best times), training 
details in the last 15 weeks before the event (training distances and hours 
spent training); and (3) personal general medical history. In the general 
medical history section of the questionnaire, triathletes were asked to report a 
history of any medical problems in 14 speci'f!c areas. These included the 
presence of RTS (in the questionnaire these were termed 'flu-like' symptoms 
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to avoid medical tenninology that triathletes may not understand) in the 6 
weeks or 1 week before the race, 
If the triathlete had a positive response to any of the abovementioned general 
medical sections, they were requested to complete a further detailed section 
of the questionnaire where more information about the specific medical 
problem was obtained. For the purposes of this study, the detailed sections of 
the questionnaire pertaining to RTS ('flu-like' symptoms) and allergies are 
relevant. As mentioned, in the questionnaires, the term 'flu-like symptoms' 
rather than RTS was used so that athletes have a clear understanding of the 
symptoms. 
In the detailed section on RTS, triathletes were asked to report the presence 
of URTS (sore throat, 'blocked', or 'runny' nose), LRTS (cough, chest pain) or 
systemic symptoms (SS) (fever, joint pain, muscle aches), and a category of 
'other' symptoms in the period 6 weeks before the race, and in the period 1 
week before the race. 
For the purposes of this thesis the following categories of symptoms are 
therefore defined: 
• URTS - upper respiratory tract symptoms 
• LRTS - lower respiratory tract symptoms 
• LRT +SS - lower respiratory tract symptoms and systemic symptoms 
• RTS - all respiratory tract symptoms and systemic symptoms (URTS, LRT, 
and SS) 
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In the detailed section on allergy history, triathletes were asked to report on 
the duration of allergies, current or past type of allergy (hay fever, sinusitis, 
skin allergies, eye allergies, allergies to plant material, allergies to foods, 
allergies to animals, and other allergies). In addition, triathletes were asked to 
report on medication used for allergies (cortisone nose spray/inhaler, anti-
histamine tablets, cortisone cream, anti-histamine cream, and other inhalers 
tablets or cream). Information about specific current allergy symptoms 
(sneezing, itchy runny nose, headaches, itchy palate, streaming eyes, itchy 
eyes, blocked nose, post-nasal drip, coughing, fatigue, wheezing and poor 
sleep), as well as information about the seasonal nature of the allergies (by 
calendar month) was also obtained. 
Finally, triathletes were requested to complete a detailed section on family 
history. For the purposes of this study, a positive family history for asthma and 
allergies will be reported. 
3.2.4. Environmental conditions on race day 
Data on the weather conditions on race day were obtained from the South 
African Weather Service. The average temperature during the race was 20°C 
(maximum temperature of 21°C, minimum temperature of 19°C). The average 
relative humidity during the race was 70%, and the average wind speed was 
37 km/h. The sea temperature during the swim component was recorded as 
19.2°C. 
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3.2.5. Statistical analysis of data 
All the data from the questionnaires were entered on to an Excel spreadsheet 
(Microsoft 2003). Data were analysed using the Statistica 7.0 (Stat-soft Inc, 
Tulsa, Oklahoma, USA) and GraphPad InStat 2.0Sa (GraphPad Software, 
San Diego, California, USA) statistical programs. All numerical data are 
represented by the mean ± standard deviation, with the number of subjects in 
parenthesis. A one-way analysis of variance (ANOVA) was used to determine 
any significant differences between groups. Where the overall F value was 
significant, a Turkey's honest significant difference post hoc test was used to 
identify where the differences were. CategOrical data are expressed as 
frequencies, and significant differences between groups were analyzed using 
the Pearson's chi-square or Fisher's exact tests. The numbers of subjects or 
observations (n) are usually in parenthesis. Statistical significance was 
accepted when p<O.OS. 
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3.3. Results 
3.3.1. General medical conditions in Iron man triathletes 
The general medical conditions reported by the triathletes (male and female) 
in this sample are depicted in Table 3.1. 
Table 3.1. The general medical conditions of a sample of triathletes 
(male and female) who entered the 2006 South African Ironman Triathlon 
All Male Female 
p-yalue • 
(n=304) (n=253) (n=51 ) 
Respiratory tract symptoms (%) b 49.2 (299) 48.4 (248) 52.9 (51) 0.661 
Muscle Cramping (%) 52.2 (301) 56.0 (250) 33.3 (51) 0.005 
Tendon I Ligament injuries (%) 38.3 (300) 39.4 (249) 33.3 (51) 0.517 
Medicines (%) C 28.9 (301) 26.8 (250) 39.2 (51) 0.107 
Gastrointestinal Symptoms (%) d 44.2 (301) 42.0 (250) 54.9 (51) 0.125 
Nervous system Sym ptoms (%) 17.0 (300) 14.8 (250) 28.0 (50) 0.039 
Genital area injuries (%) 23.9 (301) 22.8 (250) 29.4 (51) 0.407 
Allergies (%) 36.3 (300) 37.0 (249) 33.3 (51) 0.742 
Asthma (%) 9.6 (301) 9.6 (250) 9.8 (51) 0.829 
Exercise-associated Collapse (%) 6.6 (301) 6.0 (250) 9.8 (51) 0.493 
Current injuries (%) 26.3 (297) 26.3 (247) 26.0 (50) 0.897 
Sunburn (%) 40.2 (291) 40.1 (242) 40.8 (49) 0.949 
Skin cancer (%) 2.5 (278) 2.5 (236) 2.4 (42) 0.636 
Other skin damage (%) 3.7 (267) 3.0 (230) 8.1 (37) 0.299 
Values are expressed as a frequency (%) with the number of subjects (n) in parentheses. 
a Male vs. female triathletes 
b Six weeks before the race. 
C Used medicines to treat injuries in the week before or during a race. 
d During exercise. 
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The most commonly reported medical complaint in this group of triathletes 
was muscle cramping (52%) followed by respiratory tract symptoms (RTS) 
(49%), gastrointestinal symptoms (44%), a history of sunburn (40%) and 
allergies (36%). A history of tendon or ligament injuries was reported in 38% 
of triathletes, while 26% reported a current injury. 
3.3.2. Respiratory tract symptoms (RTS) in Ironman triathletes 
In this sample. 147 triathletes reported having RTS during either the 6-weeks 
or 1-week period before the race. The age, height. self-reported body weight. 
8MI. gender. country of origin, country of residence, performance in the 
triathlon (swim. cycle, run and overall), in the triathletes who reported RTS 
and those who did not report any RTS in the 6 weeks before the race is 
depicted in Table 3.2. Triathletes who reported RTS in the 6 weeks before the 
race were significantly younger, and reported a higher frequency of being bom 
in South Africa compared with those who did not report RTS. There was, 
however, no significant difference in the RTS of the triathletes based on their 
country of present residence (p=0.151). The performance time in the swim, 
cycle and run legs, as well as the overall time, was not affected by RTS. A 
similar number of triathletes (>93%) successfully completed the event in each 
group (p=0.124). 
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Table 3.2. The physical characteristics and performance parameters of 
the triathletes who reported RTS during the 6 weeks before the race 
NoRTS RTS Co-varled p-
(n=152) (n=147) 
p-value value a 
Age (years) 39.7 ± 9.4 (142) 36.7 ± 7.6 (135) 0.004 n.d. 
Height (em) 178.2 ± 8.8 (134) 177.9 ± 7.9 (133) 0.782 n.d. 
Weight (kg) b 74.0 ± 10.5 (144) 75.3 ± 11.5 (142) 0.338 n.d. 
BMI (kglm2) c 23.5 ± 2.4 (132) 23.7 ± 2.5 (133) 0.325 n.d. 
Gender (% male) 84.2 (152) 81.6 (147) 0.661 n.d. 
Country of Birth (% South Africa) d 66.0 (141) 81.2 (138) 0.006 n.d. 
Country of Residence (% South 
80.3 (152) 87.1 (147) 0.151 n.d. Africa) 
Swim Time (min) 89± 16 (146) 89 ± 15 (144) 0.717 0.439 
Cycle Time (min) 407 ± 40 (143) 409 ± 41 (142) 0.774 0.365 
Run Time (min) 295± 51 (141) 296 ± 53 (143) 0.871 0.483 
Overall Time (min) 789 ± 94 (142) 793 ± 95 (144) 0.711 0.262 
Finished Irooman Triathlon (%). 93.4 (152) 98.0 (147) 0.124 n.d. 
Values are expressed as either an average ± standard deviation or a frequency (%). The 
number of subjects (n) is in parentheses. 
n.d., not determined. 
a Co-varied for age. 
bWelght is the athletes self-reported normal body weight. 
C Body mass index (BMI) Is calculated as weight (kg) divided by height (m) squared. 
d 22 Africa, 1 Asia, 4 Central and North America, 42 Europe, 2 Middle East, 2 New Zealand 
and 1 Mauritius. 
e 7 did not start and 6 did not finish the Ironman Triathlon. 
The history of smoking, allergies, family history of allergies and asthma in the 
triathletes who reported RTS and those who did not report RTS is depicted in 
Table 3.3. 
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Table 3.3. The history of smoking, allergies, and family history of 
allergies and asthma of the triathletes who reported RTS during the 6 




Current and Ex-smokers (%) a 30.9 (152) 26.9 (145) 0.525 
Allergies (%) 25.8 (151) 46.9 (147) <0.001 
Asthma (%) 9.9 (152) 9.5 (147) 0.924 
Family History of Allergies (%) 35.6 (146) 45.0 (140) 0.134 
Family History of Asthma (%) 29.1 (148) 39.4 (142) 0.082 
Values are expressed as either an average ± standard deviation or a frequency (%). The 
number of subjects (n) is in parentheses. 
1 
a 6 triathletes are current smokers. The current and ex-smokers smoked on average 16 ± 11 
cigarettes per day for 10.1 ± 6.1 years, and the ex-smokers stopped smoking on average 10.4 
± 8.4 years ago. 
There were also no significant difference in RTS (26.9%) and no RTS (30.9%) 
amongst current and past smokers (p=0.525). Triathletes who reported RTS 
in the 6 weeks before the race had a significantly greater reported frequency 
of allergies (47%), compared to triathletes who did not report RTS in the 6 
weeks before the race (26%) (p<0.001). A self-reported history of asthma was 
not associated with RTS (p=0.924), and neither was a family history of 
allergies (p=O .134). However, there was a trend observed between a family 
history of asthma and RTS in the 6 weeks before the race (p=0.082). Similar 
results for the physical characteristics, performance parameters, and history 
of smoking and allergies, as well as the family history for allergies and 
asthma, were obtained when only the South African-born triathletes or only 
those resident in South Africa were analyzed (data not shown). The mean 
numbers of years that triathletes suffered from allergies was 19.7 ± 13.3 years 
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(n=66), and there was no significant difference in the number of years 
between subgroups of triathletes reported suffering from allergies (p=O.124). 
3.3.3. Upper respiratory tract symptoms (URTS) and lower respiratory 
tract and/or systemic symptoms (LRT+SS) in trlathletes 
Triathletes who reported RTS before the race were further subdivided into 
those with only upper respiratory tract symptoms (URTS), which included 
blocked or runny nose, and those with either systemic lower respiratory tract 
or systemic symptoms or both (LRT +SS) (fever, cough, chest pain, wheeze, 
muscle aches and pains). Sixty-seven triathletes had symptoms during both 
the 6-week and during the one-week pre-race period. Four triathletes only had 
symptoms during 1 week before the race (not the 6 weeks), and 68 had 
symptoms during the 6-weeks period, but none during the week before the 
event. 
The physical characteristics and performance parameters of triathletes who 
reported no RTS and either URTS or LRT +SS during the 6 weeks before the 
race are presented in Table 3.4. 
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Table 3.4. The physical characteristics and performance parameters of 
the triathletes who reported no RTS, and either URTS or LRT+SS during 
the 6 weeks before the race 
NoRTS URTS LRT+SS Co-varied 




Age (years) 39.8 ± 9.3 (144) d.a 35.7 ± 7.7 (41)d.f 36.3 ± 8.2 (65) e.1 '0.019 n.d. 
10.930 
Height (em) 178.3 ± 8.8 (135) 179.0 ± 8.9 (41) 177.2 ± 7.6 (64) 0.522 n.d. 
Weight (kg) b 74.0 ± 10.7 (146) 76.3 ± 12.3 (43) 75.9 ± 11.6 (68) 0.342 n.d. 
BMI (kglm2) c 23.4 ± 2.4 (133) 23.8±2.5(41) 24.0 ± 2.6 (64) 0.312 n.d. 
Gender(% 83.8 (154) 84.1 (44) 82.9 (70) 0.981 n.d. male) 
Allergies (%) 25.5 (153) 52.3 (44) 44.9 (69) <0.001 n.d. 
Swim Time 
89 ±16 (148) 87:t14 (44) 92 ± 17 (68) 0.284 0.168 (min) 
Cycle Time 
d 0.777 d 0.922 
407 ± 39 (145) d •• 402 ± 36 (44)d,f 420 ± 47 (66) e,1 • 0.088 • 0.014 (min) 10.070 10.083 
d 0,609 d 0.571 
Run nme (min) 295 :t 50 (143) d,e 286 ± 46 (44) d,1 312 ± 59 (67) e,f • 0.066 ·0.010 
'0,029 10.019 
Overall nme 
c 0.686 d 0.851 
789 :t 92 (144) d,e 775 :t76 (44)d.f 823 ± 109 (67) a,1 • 0.039 • 0.004 (min) 
'0.026 '0.022 
With the exception of gender and allergies. which are expressed as frequencies (%). the 
remaining values are expressed as an average ± standard deviation. The number of subjects 
(n) is in parentheses. 
n.d .• not determined. 
a Co-varied for age. 
bWeight Is the athletes self-reported normal body weight. 
C BodJ mass index (BMI) is calculated as weight (kg) divided by height (m) squared. 
d. e. a f p values as depicted in the column "p-valuen 
The triathletes that reported either URTS (p=O.020) or (p=O.019) LRT +SS 
were on average significantly younger than those who did not report any RTS. 
There was no Significant difference in the ages of subgroups of triathletes who 
reported URTS or LRT+SS (p=O.930). When co-varied for age differences. the 
triathletes with LRT +SS completed on average the cycle. run and overall 
event slower than the triathletes with no RTS or URTS. URTS did not appear 
to affect the athletes' performance during the triathlon. However. both 
50 
subgroups of triathletes with either URTS (52%) or LRT +SS (45%) reported a 
significantly higher prevalence of allergies compared with triathletes reporting 
no RTS during the 6 weeks before the race (p<O.001). 
Triathletes who reported no RTS, and either URTS or LRT +SS during the 1 
week before the race are presented in Table 3.5. In these groups, there were 
no significant differences in the average age of the triathletes. Those with 
URTS or LRT +SS were, however, significantly heavier than those with no 
RTS. As before, the triathletes with either URTS or LRT +SS in the period 1 
week before the race reported significantly greater prevalence of allergies 
compared to the triathletes reporting no RTS (p<O.001). Triathletes reporting 
LRT +SS in the 1 week period before the race were also slower in all three 
legs and the in the overall time for the triathlon when compared to triathletes 
with either no RTS or only URTS. The presence of URTS 1 week before the 
event also did not affect the performance of the triathletes. 
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Table 3.5. The physical characteristics and performance parameters of 
the triathletes who reported no RTS, URTS, or LRT+SS 1 week period 
before the race 
NoRTS URTS LRT+SS Co-varied 
(n=218) (n=35) 
p-value 
p-value • (n=29) 
Age (years) 38.8 :t 8.9 (207) 36.2 :t 7.2 (29) 36.2 :t 9.1 (27) 0.145 n.d. 
Height (em) 177.6:t 8.8 (193) 179.5 :t 7.8 (33) 180.4:t 6.6 (28) 0.187 n.d. 
Weight (kg) b 74.3:t 11.1 (209) 77.2:t 11.4 (33) 78.9 :t 9.4 (28) 0.065 n.d. 
8MI (kglm2) • 23.6:t 2.5 (191) 23.9 :t 2.6 (33) 24.2 :t 1.9 (28) 0.446 n.d. 
Gender (% male) 83.9 (218) 80.0 (35) 86.2 (29) 0.781 n.d. 
Allergies (%) 30.1 (216) 65.7 (35) 48.3 (29) <0.001 n.d. 
d 0.195 d 0.089 
Swim Time (min) 89 :t16 (210) d •• 84 :t 13 (35) d.' 95:t 16 (29) • .1 • 0.147 • 0.053 
'0.017 '0.002 
d 0.768 d 0.419 
Cycle Time (min) 407 :t 42 (207) d., 401 :t 40 (35) d.l 426 :t 39 (27) '.' • 0.051 ·0.028 
'0.048 '0.014 
d 1.000 d 0.596 
Run Time (min) 293 :t 52 (206) d •• 293 :t 56 (35) dJ 323 :t 49 (27) "" • 0.016 • 0.038 
'0.074 '0.063 
Overall Time 
d 0.883 d 0.381 
787 :t 97 (207) d.' 779 :t 91 (35) dJ 844 :t 90 (27) •. , • 0.011 ·0.014 (min) '0.022 '0.007 
With the exception of gender and allergies, which are expressed as frequencies (%), the 
remaining values are expressed as an average ± standard deviation. The number of subjects 
(n) is in parentheses. 
n.d., not determined. 
a Co-varied for age, gender and self-reported normal body weight. 
bWeight is the athletes self-reported normal body weight. 
C BodJ mass index (BMI) is calculated as weight (kg) divided by height (m) squared. 
d, e. a f p values as depicted in the column "p-value" 
The triathlon (sprint, standard, half Ironman and Ironman) and road running (5 
km, 10 km. 21.1 km and 42.2 km) personal best times (PB). as well as the 
best times achieved over the last 12 months in triathlons or 15 weeks in road 
running races in the no RTS, URTS and LRT +SS groups during the 6 weeks 
and 1 week before the race are presented in Tables 3.6. and 3.7. respectively. 
There were no significant differences in the life-long personal best times of the 
three groups of athletes in any of the triathlon or road running events (Tables 
3.6. and 3.7.). Similarly. there was also no significant difference in the best 
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times achieved by the triathletes in any of the 4 triathlon disciplines during the 
12 months before the 2006 South African Ironman Triathlon. With the 
exception of a significant difference in the 21.1 km best time achieved by the 6 
weeks URTS and the LRT +SS groups during the 15 weeks before the 
lronman (Table 3.6.), there were no other significant performance difference in 
the road running disciplines between the groups (Tables 3.6. and 3.7.). All the 
groups of triathletes competed in a similar number of standard lronman 
triathlons during the last 2 years (data not shown). 
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Table 3.6. The triathlon (sprint, standard, half Ironman and Ironman) and 
road running (5 km, 10 km, 21.1 km and 42.2 km) personal best times 
(PB) and best times achieved over the last 12 months or 15 weeks of the 
triathletes who reported no RTS, URTS, or LRT+SS during the 6 weeks 
before the race 
NoRTS URTS LRT+SS Co-varied p-value 
p..yalue • (n=154) (n=44) (n=70) 
Sprint PB (min) 73± 17 (76) 72±9 (28) 75 ± 16 (38) 0.712 n.d. 
Standard PB (min) 147 ± 27 (84) 140±22 (23) 150± 27 (32) 0.340 n.d. 
Half Ironman PB (min) 333 ±49 (88) 328± 32 (21) 336 ±43 (37) 0.830 n.d. 
Ironman PB (min) 737 ± 102 (68) 748 ± 56 (14) 770 ± 110 (28) 0.350 n.d. 
Sprint 12 Months (min) 78 ± 20 (51) 78 ± 17 (18) 78 ± 18 (21) 0.999 0.944 
Standard12 Months 153 ± 30 (60) 143 ± 25 (18) 156± 27 (25) 0.321 
0.199 
(min) 
Half Ironman 12 
339± 47 (61) 329 ± 36 (15) 
348 ± 39 (27) 0.411 0.573 
Months (min) 
lronman 12 Months 
764 ± 104 (53) 755±64 (10) 780± 112 (21) 0.775 
0.290 
(min) 
5 km PB (min) 20 ±4 (84) 20± 3 (23) 21 ± 3 (30) 0.373 n.d. 
10 km PB (min) 41 ±6(116) 42±7 (30) 43±7(51) 0.124 n.d. 
21.1 km PB (min) 95 ± 14 (129) 94± 15 (27) 98 ± 15 (55) 0.431 n.d. 
42.2 km PB (min) 210 ± 30 (113) 209±25 (23) 217 ± 31 (42) 0.761 n.d. 
5 km 15 weeks (min) 22 ± 5 (39) 22 ± 3 (9) 21±4(11) 0.923 0.965 
10 km 15 weeks (min) 45 ± 6(56) 47±6(18) 46±6(17) 0.561 0.359 
21.1 km 15 weeks (min) 104 ± 15 (70) 100±11 (16) 111±16(28) 0.036 0.033 
42.2 km 15 weeks (min) 230 ± 42 (49) 207 ± 28 (9) 228 ± 20 (14) 0.316 0.486 
Values are expressed as average ± standard deviation, with the number of subjects (n) in 
parentheses. 
PB. personal best time; n.d., not determined. 
a Co-varied for age and gender. 
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Table 3.7. The triathlon (sprint, standard, half Ironman and Ironman) and 
road running (5 km, 10 km, 21.1 km and 42.2 km) personal best times 
(PB) and best times achieved over the last 12 months or 15 weeks of the 
triathletes who reported no RTS, URTS, or LRT+SS during the 1 week 
before the race 
NoRTS URTS LRT+SS Co-varled p-value 
p-value (n=218) (n=35) (n=29) 
Sprint PB (min) 74 ± 17 (107) 71 ± 10 (24) 75 ± 13 (18) 0.660 0.412b 
Standard PB (min) 146 ± 28 (112) 140 ± 20 (22) 155± 22 (15) 0.237 0.137 b 
Half Irooman PB 
332 ± 47 (121) 320 ± 34 (21) 351 ± 40 (16) 0.099 
O.068 b 
(min) 
Ironman PB (min) 739 ± 105 (94) 745±97 (15) 786± 85 (8) 0.455 0.483 b 
Sprint 12 Months 
79 ± 21 (72) 74± 8 (14) 76± 14 (9) 0.558 
0.330 a 
(min) 
Standard 12 153 ± 31 (81) 146±21 (16) 
154 ± 21 (14) 0.669 
0.064 a 
Months (min) 
Half Irooman 12 34U47 (86) 325± 42 (is) 367 ± 35 (10) 0.069 
0.116 a 
Months (min) 
Irooman 12 Months 765 ± 103 (72) 759 ± 116 (12) 778 ± 117 (6) 0.936 
0.665 a 
(min) 
5 km PB(min) 20 ± 3 (119) 20± 3 (20) 20±3(12) 0.873 0.298 b 
10 km PB (min) 42 ± 6 (170) 42 ± 6 (23) 45± 6 (is) 0.082 0.212 b 
21.1 km PB (min) 95± 15 (179) 94 ± 12 (23) 100 ± 14 (22) 0.314 0.197
b 
cO.122 
42.2 km PB (min) 20S ± 29 (154) c,d 221 ± 32 (20) c .• 227 ± 26 (17) d •• d 0.026 0.109b 
80.825 
5 km 15 weeks (min) 22 ± 4 (54) 20 ± 3 (9) 22 ± 7 (3) 0.579 0.296 a 
10 km 15 weeks 
cO.S34 
45 ± 6 (76) Cod 45 ± 5 (17) c,d 51 ± 7 (S) Cod d 0.039 0.093-
(min) ·0.036 
21.1 km 15 weeks 105 ± 16 (102) 103 ± 12 (17) 116 ± 11 (7) 0.136 
0.240-
(min) 
42.2 km 15 weeks 230± 46 (52) 21S±29 (11) 242 ± 28 (4) 0.563 
0.445-
(min) 
Values are expressed as average ± standard deviation, with the number of subjects (n) in 
parentheses. 
PB, personal best time. 
S Co-varied for age, gender and self-reported normal body weight. 
b Co-varied for gender and self-reported normal body weight. 
d. e. and f p values as depicted in the column up-value" 
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3.3.4. RTS and training in triathletes preparing for the Ironman 
The training frequencies, times and distances during the 15 weeks and 1 
week prior to the Iron man for the no RTS, URTS and LRT +SS groups during 
the 6 weeks and 1 week before the triathlon are depicted in Tables 3.8. and 
3.9., respectively. Athletes with LRT +SS during the 6 weeks prior to the event 
trained significantly less than those with either no RTS or only URTS (Table 
3.8.). Training frequency was, however, not significantly different between the 
groups of triathletes reporting RTS 1 week before the event (Table 3.9.). In 
addition, triathletes reporting LRT +SS during the 6 weeks (Table 3.8.) and 1 
week (Table 3.9.) before the race completed significantly less running, but not 
cycling or swim distances per week than the triathletes with no RTS or only 
URTS. The time per week spent training for each component of the triathlon 
during this period was similar between the various groups of triathletes. 
Except for significant differences in the running time and distance per week by 
the triathletes reporting RTS during the week before the triathlon (Table 3.8.), 
the groups of triathletes trained for similar durations and times during the 7 
days prior to the triathlon (Tables 3.8. and 3.9.). 
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Table 3.8. The training distances and durations (swimming, cycling, 
running and total) for the period 1 week and 15 weeks before the 
Ironman of the trlathletes groups with no RTS, URTS and LRT+SS during 
the 6 weeks before the triathlon 
NoRTS URTS LRT+SS 
(n=154) (n=44) (n=70) 
p-value 
Training Frequency • 0.271 5.8 ± 0.9 (140) .. b 6.0 ± 0.7 (41) a.e 5.4 ± 1.1 (65) b.e bO.037 
(dayslwk) c 0.004 
Swim Time 15wk (minlwk) 185 ± 95 (147) 200 ± 76 (41) 184 ± 106 (62) 0.641 
Cycle nme 15wk (minlwk) 489 ± 182 (147) 528± 174 (41) 473 ± 199 (63) 0.321 
Run Time 15wk (mlnlwk) 293 ±109 (141) 306 ± 112 (38) 261± 93 (54) 0.093 
Total nme 15 wk (minlwk) 962 ± 274 (138) 1044 ± 287 (38) 907 ± 267 (54) 0.065 
Swim Dlat 15 wk (kmIwk) 6.3 ± 3.3 (149) 7.4±2.9(41) 6.3 ± 3.2 (63) 0.130 
Cycle Dlat 15 wk (kmlwk) 218 ± 82 (146) 239 ±89 (41) 214 ± 86 (62) 0.289 
• 0.945 
Run Diat 15wk (kmlwk) 49 ± 17 (144) I.b 48 ±14 (41) I.e 41 ± 13 (60) b.C b 0.003 
·0.070 
Total Dlat 15 wk (kmlwk) 275 ± 89 (143) 295 ± 97 (41) 261 ±92 (58) 0.191 
Swim nme 1 wk (minlwk) 69 ±63 (145) 61 ± 38 (41) 71 ± 74 (67) 0.709 
Cycle Time 1 wk (mlnlwk) 155 ± 144 (143) 155± 85 (38) 133 ± 110 (65) 0.479 
Run Time 1 wk (mlnlwk) 76 ±62 (145) 82 ± 60 (37) 73 ± 66 (65) 0.800 
Total nme 1 wk (minlwk) 305 ± 213 (140) 299 ± 149 (36) 283 ± 216 (61) 0.780 
Swim Dlat 1 wk (kmlwk) 2.4 ± 2.3 (147) 2.4 ± 1.5 (42) 2.4 ± 1.8 (65) 0.993 
Cycle Dlat 1 wk (kmlwk) 69 ± 57 (146) 69 ±47 (42) 55±47 (64) 0.198 
Run Dlat 1 wk (kmlwk) 13 ± 12 (138) 16 ± 11 (40) 12 ± 11 (62) 0.322 
Total Dlat 1 wk (kmlwk) 83 ± 61 (135) 89 ±54 (40) 69 ± 56 (61) 0.176 
Values are expressed as average ± standard deviation, with the number of subjects (n) In 
parentheses. 
a. b. and C p values as depicted in the column "p-value" 
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Table 3.9. The training distances and durations (swimming, cycling, 
running and total) for the period 1 week and 15 weeks before the 
Ironman of the triathletes groups reporting no RTS, URTS and LRT+SS 
during the 1 week before the triathlon 
NoRTS URTS LRT+SS 
(n=218) (n=35) (n=29) 
p-value 
Training Frequency 
5.7:t 0.9 (201) 5.7:t 0.9 (32) 5.7 :t 0.6 (26) 0.902 (dayslwk) 
Swim Time 15 wk 
187 :t 90 (205) 184:t 93 (34) 188:t 108 (24) 0.980 (minlwk) 
Cycle Time 15 wk 
499:t 192 (204) 494 :t 150 (33) 444 :t 180 (25) 0.385 (minlwk) 
Run Time 15 wk (minlwk) 289:t 104 (193) 319:t 107 (31) 254 :t 111 (22) 0.085 
Total Time 15 wk (minlwk) 968:t 276 (190) 1003 :t 258 (30) 880 :t 261 (22) 0.256 
Swim Dlat 15wk (kmlwk) 6.5 :t 3.2 (206) 7.3:t 4.1 (33) 6.5 :t 3.1 (27) 0.430 
Cycle Dlat 15 wk (kmlwk) 222 :t 88 (202) 246:t 104 (33) 215 :t 78 (27) 0.313 
• 0.456 
Run Dlat 15 wk (kmlwk) 48:t 17 (200) a,b 51 :t 16 (32) •. C 104:t 11 (26) b.. b 0.083 
·0.029 
Total Dlat 15 wk (kmlwk) 278 :t 96 (198) 306:t 118 (32) 259:t 74 (24) 0.173 
SwIm Time 1 wk (minlwk) 71 :t58 (208) 69:t60 (34) 61 :t93 (26) 0.765 
Cycle Time 1 wk (minlwk) 158 :t133 (205) 171 :t108 (31) 107 :t99 (25) 0.124 
Run Time 1 wk (minlwk) ·0.351 
79:tel (207) S,D 99 :t74 (30) •.• 50 :tOO (25) b,. bO.069 
• 0.011 
Total Time 1 wk (minlwk) 312:t 203 (201) 346 :t 218 (29) 216 :t 206 (22) 0.064 
SwIm Dlat 1 wk (kmlwk) 2.5 :t2.2 (205) 2.5 :tl.9 (34) 2.1 %2.1 (28) 0.620 
Cycle Dlat 1 wk (kmlwk) 68 :t55 (203) 72 :t51 (34) 53 :t49 (28) 0.309 
• 0.044 
Run Dlat 1 wk (kmlwk) 13 :t11 (192) S,D 18 :t12 (33) a.c 10 :t11 (28) D.e bO.345 
c 0.012 
Total Dlat 1 wk (kmlwk) 83 :t 59 (188) 95:t 59 (33) 65:t 58 (28) 0.146 
Values are expressed as average ± standard deviation, with the number of subjects (n) in 
parentheses. 
a. b. and C p values as depicted in the column "p-value" 
Triathletes who reported LRT +SS during the 6 weeks prior to the event 
predicted that they would run (296 ± 58 min, n=66, pSO.017), but not swim 
(p=0.355) or cycle (p=0.515), significantly slower than triathletes reporting no 
RTS (275 ± 45 min, n=147) or only URTS (271 ± 40 min, n=44) during the 6 
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week period. There was also no significant differences in the overall predicted 
times between these groups of triathletes (p=0.170) (data not shown). 
Similarly, the triathletes reporting LRT +SS during the 7 days prior to the event 
predicted that they would run significanUy slower (301 ± 57 min, n=27) than 
triathletes with no RTS (276 ± 47 min, n=209) during this period (p=0.032) 
(data not shown). Those reporting URTS during this 1 week period predicted 
that they would run on average for 277 ± 54 min (n=35). There were no 
significant differences in the triathlete's relative overall or split times when 
their actual times were expressed relative to there predicted times (data not 
shown). 
3.3.5. Different types of self-reported allergies and RTS In triathletes 
The different types of self-reported allergies in triathletes who reported URTS 
or LRT +SS in the 6 weeks or 1 week before the lronman are reported in 
Tables 3.10. and 3.11. respectively. 
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Table 3.10. The types of self-reported allergies in the triathletes groups 
with no RTS, all RTS, and either URTS or LRT+SS during the 6 weeks 
before the Ironman 
NoRTS URTS LRT+SS All RTS 
(n=33) (n=22) (n=32) 
p-value • 
(n=54) 
Nose (Hay Fever) % 25 (75.8) 13 (59.1) 22 (68.8) 0.424 35 (64.8) 
Sinusitis (%) 18 (54.6) 14 (63.6) 18 (56.3) 0.788 32 (59.3) 
Asthma (Allergy) 
26 (78.8) 19 (86.4) 26 (81.3) 0.775 
45 (83.3) 
(%) 
Skin Allergies (%) 6 (18.2) 1 (4.6) 9 (28.1) 0.089 10 (18.5) 
Eye Allergies (%) 4 (12.1) 3 (13.6) 8 (25.0) 0.340 11 (20.4) 
Allergy to Plant 
3 (9.1) 5 (22.7) 3(9.4) 0.258 
8 (14.8) 
Material (%) 
Allergy to Food (%) 29 (87.9) 20 (90.9) 28 (87.5) 0.919 48 (88.9) 
Allergy to Animals 
11 (33.3) 3 (13.6) 6 (18.8) 0.182 
9 (16.7) 
(%) 
other Allergies (%) 31 (93.9) 20 (90.9) 31 (96.9) 0.561 51 (94.4) 
Values are expressed as the number of observations (n). with the frequency (%) in 
parentheses. 
a No RT5 VS. URT5 VS. LRT +55. 











There were no Significant differences in the reported occurrence of no RTS, 
URTS, LRT+SS and all RTS for all types of reported allergies in triathletes 6 
weeks before the triathlon. At 1 week before the triathlon, triathletes with 
sinusitis reported significantly more URTS rather than LRT +SS (p=O.038). 
Allergy to animals was more common in triathletes who reported no RTS in 
the 1 week period before the race (p=O.025) (Table 3.11.) 
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Table 3.11. The types of self.reported allergies in the triathletes groups 
with no RTS, all RTS, and either URTS or LRT +SS in the 1 week before 
the Ironman 
NoRTS URTS LRT+SS All RTS p-value 
(n=56) 
p-value a b 
(n=23) (n=16) (n=39) 
Nose (Hay Fever) 
42 (75.0) 15 (65.2) 11 (68.8) 0.656 26 (66.7) 0.513 
% 
Sinusitis (%) 30 (53.6) 19 (82.6) 8 (50.0) 0.038 27 (69.2) 0.187 
Asthma (Allergy) 46 (82.1) 22 (95.7) 11 (68.8) 0.083 33 (84.6) 0.970 (%) 
Skin Allergies (%) 10 (17.9) 4 (17.4) 3 (18.8) 0.994 7 (17.9) 0.794 
Eye Allergies (%) 11 (19.6) 4 (17.4) 3 (18.8) 0.973 7 (17.9) 0.953 
Allergy to Plant 7 (12.5) 5 (21.7) 2 (12.5) 0.553 
7 (17.9) 0.658 
Material (%) 
Allergy to Food 49 (87.5) 20 (87.0) 15 (93.8) 0.764 
35 (89.7) 0.992 
(%) 
Allergy to 19 (33.9) 6 (26.1) 0(0.0) 0.025 
6 (15.4) 0.075 
Animals (%) 
other Allergies 54 (96.4) 21 (91.3) 16 (100.0) 0.627 37 (94.9) 0.883 
(%) 
Values are expressed as the number of observations (n), with the frequency (%) in 
parentheses . 
a No RTS VS. URTS VS. LRT +SS. 
b No RTS VS. All RTS. 
3.4. Discussion 
The main findings in this study are that, 1) RTS are commonly reported by 
Ironman triathletes in the 6 week period before competition (49% of 
triathletes), 2) there is a strong association between self-reported RTS in 
Ironman triathletes (reported in the period 6 weeks and 1 week before the 
race) and a history of self-reported allergies rather than training volume (in the 
15 weeks before the race), 3) self-reported LRT+SS but not URTS in 
triathletes are associated with decreased training in the 6 weeks before the 
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race, 4) self-reported LRT +SS but not URTS in triathletes result in reduced 
pre-race training, predicted race performance, and actual race performance, 
and 5) there is no specific self-reported allergy that is associated with all RTS, 
URTS or LRT +SS in Ironman triathletes. 
Medical conditions other than RTS are also commonly reported by triathletes 
while preparing for an lronman competition. Muscle cramping (52%), gastro-
intestinal symptoms (44%), history of sunburn (40%), a history of 
tendonlligament injuries (38%), allergies (36%) and genital injuries (24%) 
were the most common other reported medical problems in this group of 
triathletes. 
In our study we documented that almost 50% of the triathletes reported RTS 
in the 6 week period before the race. In the 6 week period before the race, 
44/268 (16%) of these triathletes reported URTS, while 70/268 (26%) reported 
LRT+SS. In the last week before the race, 35/282 (12.4%) reported URTS, 
while 29/282 (10.3%) reported LRT+SS. This is a very high incidence and 
clearly indicates that RTS are very common in these athletes, particularly 
during the intense pre-race training period. Yet, despite previous data showing 
that increased training volume is associated with an increased risk of RTS, 
triathletes presenting with RTS in our sample did not have higher training 
volumes in the 15 weeks before the race, compared to those triathletes who 
did not present with RTS. Rather, RTS in triathletes was associated with a 
younger age, being born in South Africa, and a self-reported history of 
allergies. Smoking history, a history of allergies, a history of asthma, a family 
history of allergies, calibre of the triathlete (personal best times in components 
62 
of the triathlon) and a family history of asthma were not related to RTS. It is 
important to note that country of residence was not related to a RTS, and this 
is perhaps a more important parameter than country of origin, because 
exposure to different environmental conditions (temperature, humidity, altitude 
and aero-allergens) is more likely to affect risk of developing RTS. In our 
subsequent analysis, the younger the age of the triathletes with RTS was 
taken into account (co-varied). In this analysis, the history of self-reported 
allergies still remained the most significant factor that was associated with 
RTS (URTS, and LRT +SS) in this group of triathletes. However, we could not 
identify a specific type of allergy that was associated with any RTS, or URTS 
and LRT +SS subgroups. 
There are no studies in triathletes that we can directly compare our findings 
to. However, the frequency of RTS in the pre-race period in our study is 
comparable to that reported for the post-race period in marathon runners (33-
68%) 2;3. However, we could not confirm the previously documented 
association between RTS and faster runners 2, nor did we show an 
association between increased training and the development of RTS 25;45;57. 
Our data that 36% of all the triathletes reported allergies, is similar to that 
recently documented for endurance athletes (44%)71. A novel finding, not 
previously reported elsewhere, is that this prevalence of allergies is twice as 
high in triathletes experiencing RTS in the 6-week period before a race (47%), 
compared to triathletes with no RTS in the period 6 weeks before the race 
(26%). It is also of interest to note that the prevalence of allergies was highest 
in the URTS subgroup (66%), compared with the LRT +SS group (48%) and 
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the no RTS group (30%). Therefore allergies are associated with RTS in the 6 
weeks prior to a race, and this is not affected by calibre of the athletes, nor the 
training volume. The hypothesis that RTS in endurance athletes could be, at 
least in part, due to an allergic origin clearly requires further investigation. 
We acknowledge that one of the main limitations of our study is the fact that 
all our data on RTS, training and allergies are self-reported, and is also based 
on recall over a period of weeks. We were also not able to conduct any 
special tests to verify the presence of allergies, or to exclude infections as a 
cause of RTS in these athletes. Therefore our data have to be interpreted with 
these limitations in mind. However, the strengths of our study are 1) that we 
have a large sample size, 2) we used questionnaires that were previously 
validated, and 3) that our methodology (questionnaire survey) did not differ 
from studies that were previously conducted in similar groups of athletes to 
document either URTS 2;3;25;55;56 or allergies 71;107;110. 
One of the other main findings in our study is that RTS affects training in the 
pre-race period, as well as performance on race day. We showed that 
triathletes reporting LRT +SS trained less, reported a slower predicted race 
time, and performed slower on race day. The relationship between pre-race 
RTS in endurance athletes and training or performance has, to our 
knowledge, not been previously reported. Therefore there are no studies that 
we can compare our results to. However, it is of interest to note that triathletes 
in the LRT +SS group, had symptoms which were 'below the neck' (LRT 
symptoms or systemic symptoms). This may well indicate a more systemic 
illness rather than a localized illness. It is tempting to speculate that perhaps 
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this was a sub-group of athletes where an allergy resulted in a subsequent 
infection, giving rise to systemic symptoms. The presence of an infective 
episode that is associated with systemic symptoms has been shown to reduce 
muscle strength and endurance 119-121. This could explain the reduced 
training, the predicted slower race time, and the actual slower race time that 
we documented for this sub-group. It is, however, of concern, that the athletes 
in the LRT +SS subgroup appeared to continue with training, despite the 
presence of LRT or systemic symptoms. 
In summary, this is the first study, to our knowledge, that related pre-race 
symptoms to training and performance on race-day. These data show that. 
when triathletes experience LRT or systemic symptoms, training and 
performance is negatively affected. This would support that current clirlical 
recommendation that RTS 'below the neck' indicates a more severe condition, 
and the advice that training should not be conducted until symptoms resolve is 
correct 39-42. However, further studies are required to fully document the 
nature of these symptoms, and what is the interaction between allergies. 
infections and the development of systemic symptoms. 
Finally, in our study. we did include a section on the general medical 
conditions that triathletes report during the intense training period prior to a 
race. In this component of our study we showed that the most common 
medical condition reported by triathletes in this period is muscle cramping 
(52%), followed by RTS (49%). gastro-intestinal symptoms (44%), sunburn 
(40%). tendon/ligament injuries (38%), and allergies (36%). A detailed 
discussion of these conditions is beyond the scope of this research study, and 
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will be the focus of a subsequent analysis and report. However, we do note 
that these findings are, in general, consistent with the profile of medical 
conditions in triathletes, which was recently reviewed 1. 
In summary, the results of this study show that triathletes, in preparation for a 
race, report a high frequency of medical conditions. RTS are particularly 
common, and appear to be related to allergies rather other factors including 
training volume or the calibre of the athlete. If RTS are accompanied by LRT 
or systemic symptoms, they decrease training and negatively affect 
performance on race-day. 
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Chapter 4 
Summary and conclusion 
Respiratory tract symptoms (RTS) are common amongst triathletes in the 6 
weeks preparation period before an Ironman Triathlon, being second only to 
muscle cramping. There is a strong association between any RTS, URTS, 
and LRT +SS and self.reported allergies but no association between RTS and 
training volume, calibre of the athlete, smoking history, or family history 
(allergies or asthma). LRT +SS were associated with a reduction in training 
volume during the preparatory phase as well as performance during the 
competition. It was interesting to note that triathletes continued to train and 
participate in such an intense competition (though at a slightly reduced 
performance level), despite LRT or systemic symptoms. 
The results of this study can be applied to the current clinical 
recommendations for athletes presenting with RTS during training as follows: 
1. Sports physicians should be aware of the high incidence of general 
medical conditions in triathletes in the preparatory phase before an 
I ronman event 
2. Triathletes presenting with RTS should be assessed for the presence of 
allergic conditions, particularly those affecting the respiratory tract 
3. We recommend that an assessment to document allergies should be 
included in the current 'neck check' guideline to assess athletes presenting 
with RTS 
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4. This assessment for allergies should take the form of a clinical 
assessment, but also include special investigations to document the 
allergies 
5. The current clinical advice that athletes presenting with LRT symptoms or 
systemic symptoms should not train is supported by the results of this 
study 
6. Apart from the danger of viral myocarditis, the results of this study show 
that LRT and systemic symptoms are associated with a decrease in 
training and impairment of performance 
Finally, the results of this study clearty show that further research studies are 
needed to fully understand the relationship between RTS, allergies and 
immune parameters in athletes undergoing intense training. 
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Appendix 1: Website Information 
Welcome to 'the Spec-Savers Ironman South 
Africa Research programmme - 2006 
Dear Triathlete 
We have the privilege to inform you that scientific and medical research at the Port 
Elizabeth Spec-Savers Iron man South Africa Triathlon has been planned in 
collaboration with the UCT/MRC Research Unit for Exerdse Science and Sports 
Medidne based at the Sports Sdence Institute of South Africa, and Tswane 
University in Pretoria. This will provide a unique opportunity for a research 
programme to address important medical and physiological problems that are 
assodated with participation in the Spec-Savers Ironman South Africa triathlon. 
The research study will concentrate on the following 6 main components that will 
ultimately assist you to Improve your performance and Improve the standard of 
your medical treatment at future triathlons and other endurance events: 
• Management of the collapsed triathlete 
• Causes and treatment of Exercise-Assodated Muscle Cramping 
• Preventing post-exercise decreases in immune function and upper respiratory 
tract (URT) symptoms 
• Genetic basis for performance and physiological responses during an Ironman 
Triathlon 
• Identifying causes of chronic Achilles tendon injuries in triathletes 
• Identifying the relationship between training history, perception of effort (RPE) 
during the race and the subsequent recovery after the race. 
How can I volunteer to participate in the research study? 
As a participant in the Port Elizabeth Spec-Savers Ironman South Africa triathlon, 
you will be given the unique opportunity to participate in this research effort. Please 
understand that your participation is entirely voluntary. Please read through the 
details of the following six components of the study. You will be given the opportunity 
to participate in any number, or all the components of the study. The details of each 
component are summarized below and a detailed explanation of each component 
can be downloaded as a PDF file. If you wish to participate in the study, please 
download the information related to each component of the study (PDF file), and 
read through it carefully. Please bring the INFORMED CONSENT FORM of the study 
with you to Port Elizabeth, and then visit our RESEARCH area at the registration 
venue. Here we will discuss any questions you may have, and then sign the 
INFORMED CONSENT FORM with you. In addition please download and complete 
the QUESTIONNAIRES. We will let you know once the questionnaires are available. 
Printed copies of all the documentation will also be available at the REGISTRATION 
research area. 
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Will my participation in the research affect my preparation, 
race participation, or recovery after the race? 
All the components of this study have been carefully designed NOT to 1) interfere 
with your preparation or participation in the Ironman, 2) affect your performance on 
race day, and 3) your recovery after the event. All the tests are not painful and non-
invasive (apart from a small blood sample taken at registration and after the race). 
Will I have access to the results of the study? 
Once the study results are known, you will be able to access a summary of the 
findings of the study on the website and you can also request, this be sent to you by 
email. You will also be given the opportunity to attend a feedback meeting where the 
results of the study will be discussed. The results will only be that of the whole group, 
and no individual results will be made public. 
Who can I contact for more information? 
In the next few weeks, please feel free to contact members of the research team 
should you have any questions related to the study (or any component of the study). 
Contact details of the research team are as follows: ironman@sports.uct.ac.za or 
(021) 650 4572. 
The following documents can be downloaded:-
1. Subject information sheets 
2. Consent form 
3. Questionnaires 
4. Summarv of the study Crhis web page) 
5. Adobe Acrobat Reader 
(PDF File) 
(PDF File) 
(MS Word document) 
(PDF File) 
Summary of each component of the research study:-
1. Management of the collapsed trlathlete 
The precise causes and best treatment of collapsed endurance athletes is still 
widely debated. We would like to see if collapsed athletes have a greater 
incidence of serum sodium and plasma volume abnormalities than athletes who 
do not collapse at the end of the race. Accordingly, if these abnormalities do exist 
in collapsed athletes, are intravenous fluids superior to oral fluids in the treatment 
and restoration of sodium and plasma volume levels? Close monitoring of sodium 
levels, heart rate and blood pressure and time to discharge will help our team 
answer these questions. 
2. Exercise-associated muscle cramping 
The precise causes of Exercise-Associated Muscle Cramping (EAMC) are still 
widely debated. Contrary to popular belief. heat, dehydration and electrolyte (salt) 
abnormalities may NOT be the cause of EAMC. In this component of the study 
we would like to measure these changes in triathletes who cramp, and then follow 
what happens once we treat these athletes. We also want to measure the muscle 
"twitchiness" during the recovery period, once again trying to see If these related 
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to changes in serum electrolyte concentrations (salt). Triathletes who are prone to 
EAMC may well be interested in this component of the study. 
3. Post-exercise upper respiratory tract (URT) symptoms 
It is well documented that intense training, as well as participation in a prolonged 
strenuous endurance events (such as the Ironman) can cause changes in the 
immune system, and may increase the risk of infections (mainly of the upper 
respiratory tract). In this component of the study we want to examine the immune 
changes, as well as find out what causes the upper respiratory tract symptoms in 
endurance athletes after participation in the lronman. Triathletes that are prone to 
developing symptoms such as sore throat, runny or blocked nose or cough after a 
race may well be specifically interested in participating in this component of the 
study. 
4. Genetic basis for performance and physiological responses during an 
Iron man Triathlon 
Athletic ability is partly determined by an intervals genetic make-up. Various 
gene (DNA material) have been shown to be associated with endurance 
performance, including the South African Ironman Triathlons. In addition it has 
also been suggested that the inter-individual physiological responses, such as 
blood salt and water imbalance, as well as the development of tendon overuse 
injuries, during endurance activities is partially determined by ones genes. The 
aim of this component of the study is to identify genes associated with 
performance and susceptibility to salt and water imbalances and indicators of 
underlying tendon pathology during the Ironman Triathlon. Volunteers for this 
component of the study will be asked to complete a questionnaire. At registration 
they will be asked to donate a small blood sample from which your genetic 
material (DNA) will be extracted and your blood salt levels measured. You will 
also be weighed before the swim and again immediately after the race. A second 
blood sample will also be taken after the measure to measure your blood salt 
levels. Some volunteers will also have there Achilles tendons scanned at 
registration. 
5. Chronic Achilles tendon injuries in triathletes 
Chronic Achilles tendon injuries are common in athletes participating in weight-
bearing sports. It is well established that repetitive forces that are applied to the 
Achilles tendon (such as during running) may cause microscopic damage to the 
tendon. In the initial phases this may not cause any symptoms (pain or swelling). 
However, these changes can be observed using a technique known as soft tissue 
diagnostic ultrasound (non painful scan of the tendon). In this component of the 
study we wish to assess the changes in the Achilles tendon before and then after 
(immediately and 6 weeks later) the Ironman. In particular we wish to find out 
what damage (if any) takes place in the tendon as a result of the race, and how 
does this recover after 6 weeks. The findings of this study will also be linked to 
the genetic basis component (described in 4 above). Here we will be able to 
determine if your genetic make up determines how your tendons respond to a 
race such as the Ironman. 
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6. The relationship between training history, perception of effort during the 
race and the subsequent recovery after the race. 
The relationship between training history, perception of effort during the race and 
the subsequent recovery after the race is poorly understood. Knowing more about 
this relationship is important as it will have practical implications for the 
preparation for the race and minimise any health risks associated with too much 
physical stress which may occur after the race. Volunteers for this study will be 
asked to complete a short questionnaire on their training habits in preparation for 
the Ironman. During the race subjects will be asked to shout out a "perception of 
effort" score at they go past one of the 8 stations along the route. A researcher at 
the station will record the race number and the score. Volunteers will be sent 
emails on a daily basis for a week after the race with a short questionnaire on 
their recovery. Thereafter, they will be sent an email on a weekly basis for 12 
weeks. Volunteers living near a big centre will be asked to donate a small blood 
sample at 1, 3, 5, 7 and 9 days after the race for the measurement of creatine 
kinase, a marker of muscle damage (however, blood donations are not essential 
for entry into the study) 
If I decide to participate in the research study, what will be 
required of me? 
The following table summarises the details of your participation in the study:-
Details of Your Participation In the Study 
1. Download information sheets, questionnaires and consent forms from web page 
Before Race 2. Complete questionnaires using Microsoft Word 
3. E-mail completed questionnaires to researchers at ironman@sports.uct.ac.za 
1. Hand in and sign the informed consent forms 
2. Donate a sample of blood 
At Ultrasound scan of both Achilles tendons in some athletes (Achilles Tendon component - No 
Registration 5) 
Donate a saliva sample and have a throat swab (URT component - No 3) 
Before Swim 1. Have yourself weighed near the start of the swim before donning your wetsuit in your 
(Race Day) costume 
During Race 
1. Shout out a "perception of effort" score at they go past one of the 8 stations along the 








1. Have yourself weighed in your running gear, without shoes, at the medical tent 
2. Donate a sample of blood 
Ultrasound scan of both Achilles tendons in those athletes who had a scan during 
registration (Achilles Tendon component - No 5) 
Donate saliva samples and have throat swabs (URT component - No 3) 
Treatment of athletes with cramps and testing of unaffected volunteers (cramps component-
No 2) 
Treatment of the collapsed athletes (collapsed athlete component - No 1) 
At 6 Weeks: Ultrasound scan of both Achilles tendons (Achilles Tendon component - No 5) 
Daily for 2 Weeks: Complete symptoms questionnaire, available for telephonic surveillance 
calls every second day, and only if required, visit a designated centre for a clinical 
examination, donation of saliva and blood samples and have a throat swab taken (URT 
component - No 3) 
For 12 weeks after the race: Complete a short electronic questionnaire on your recovery 
daily for a week after the race, thereafter, on a weekly basis for 12 weeks. Volunteers living 
near a big centre will be asked to donate a blood sample at 1, 3, 5, 7 and 9 days after the 
race (however, blood donations are not essential for entry into this component of the study) 
(RPE component - No 6) 
We look forward to meeting you at the Spec-Savers Ironman South Africa 
Registration area, and wish you well in your race preparation and participation. 
Prof Martin Schwellnus, Dr Malcolm Collins, Prof Tim Noakes, and the rest of the 
Ironman Research Team 
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Appendix 2: Subject Information Sheet 
SUBJECT INFORMATION SHEET 
Dear Triathlete 
We have the privilege to inform you that scientific research at the Port Elizabeth IRON MAN 
triathlon has been planned in collaboration with the UCT/MRC Research Unit for Exercise 
Science and Sports Medicine based at the Sports Science Institute of South Africa. This will 
provide a unique opportunity for a research programme to address important medical and 
physiological problems associated with the IRONMAN triathlon. Each participant will be able 
to access a summary of the findings of the study by email, and the website. once it has been 
completed. You will also be given the opportunity to attend a feedback meeting where the 
results of the study will be discussed. The results will only be that of the whole group. and no 
individual results will be made public. 
The research study will concentrate on the following 6 main components that will ultimately 
improve your performance and improve the standard of your medical treatment at future 
triathlons and other endurance events: 
• Management of the collapsed triathlete 
• Exercise-associated muscle cramping 
• Post-exercise upper respiratory tract symptoms 
• Genetic basis for performance and physiological responses during an Ironman Triathlon 
• Chronic Achilles tendon injuries in triathletes 
• The relationship between training history. perception of effort during the race and the 
subsequent recovery after the race. 
As a participant in the Port Elizabeth IRONMAN Triathlon. you will be given the choice to 
participate in this research effort. Your participation Is entirely voluntary. Please read through 
the details of the following six components of the study. You will be given the opportunity to 
participate in one or more components of the study. The details of each component are 
explained in this document, and if you wish to participate in one or more components of the 
study. please read through and sign the INFORMED CONSENT FORMS that relate to each 
component of the study. Please feel free to contact members of the research team should you 
have any questions related to the study (or any component of the study). Contact details of 
the research team are as follows: ironman@sports.uct.ac.za or (021) 650 4572. 
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SUBJECT INFORMATION SHEET: 
COMPONENTS OF THE RESEARCH STUDY TO BE CONDUCTED AT THE 
2006 IROHMAN TRIATHLON IN PART ELIZABETH 
The res_ct-. I!ua, at the 2006 Irt)I1man Triathlon. comprase 01 six com~nentl The detailed 
nformaIlon OIl eacn 01 these com~ls of lila study Is 85 follows 
Component 1: A study on the management of the collapsed 'rlathlete 
General Information : 
The aim of IhlS study is to evaluate tM optimum !realm .. 1 strategl8S for ..... hicn to treat 
collapsed trlaUllotlll. allm an IroTYl'\3!l race AUnough iNravenou. (IV) lluod .eplacementls. 
common prac!JCe In tile IlI!lIIm9nl 01 collapsed tnalhiet85. medical penonneI need !O be 
advised ole treatment method thai wiI pr_~ possible Illud overload (nyponatraerma) whICh 
can be II Y&ry se~ere cond~1on yOU' ~Iion I1lhis tnaI will aod on Ifle undersland.ng and 
rnan&9lIffi8Ill of tlow best to CQf1'eCt any llulll imbalance following lfliS race 
II you eoItepsa duMQ 01' ellar the II"(II'InI;1In Tnathkln and are brought into tile m&dieaI lenl, you 
oMII be evaluated and treated aceoroll'lg 10 II1e curren! best 5tano:!aord or eare ~!ples Your 
legs WIll be elevated and your '-1 rs!e biood pressure, mental status and serum sod ium 
concenlfaloOO will be menured If you ate confused end )'OUI' sod .... m Iovel is normal, other 
Labormory letts d be perlormed such as an evaluallOn of your body lempan!!Ure and blood 
~ levels If your boDy Iempelature Is norma! and do no! have evidence for another 
treatable medlc8l c:oncliloon, 'n IV 1In4'.....u be IIIoced "" your arm and the appropriate ftuld will 
be adrnonklared • N or oral n",id (ad toblll,lll1 _ ~ ehoQse how much you wish 10 drink) . unt~ 
you rfIoODVef and can leaye tna medical ten! without aSllstance. Your dis.cl\arge w. be at tile 
d~etJon ol the suptlfVil~1I medICal oflk;er If your rondilOO deteriorates al any 1me. ~ w~1 
be invnedlaMJy removed from the tria l. treated appropriately and \rlJn"'llO'1ed 10 Ina nea<es\ 
-'" 
The risk of adY&rse affeela 01 olacernenl of an Intfavel'\OUl I~e Ildude O'lfecllOO. delayed 
healing, bruISing. physical pain. merltat dlscomfor1 I!Ind posSible InJUry to II nerve or vessel 
The risl< of mese OOIl9(5e a/faet. ere rare and eV8IY attemoc \0 m1nmize tnese nsks wi! be 
unOer1akeo by me use of 5ler~e tachmque and UH 01 di'oosable, Ulgie use, material YC1Ut 
~ood will be used for evaluation ollerum sodun or blood glucose concentration only No 
other tests will be perfooned on your blood and your blood ....,,01&. 'llltl be IlPOf'OPfiillety 
dlacarded after these tests afll perlormed 
.. 
We will obey the strict practices of confidentiality and anonymity. Each subject's identity will 
be known only to the researchers and numbers will be assigned to each sample in lieu of 
names. No results will be publicly available and the scientific publication of results will never 
disclose subject identity. 
Potential risks of this component of the study 
• The completion of a questionnaire is not associated with any risk. Questionnaire and 
other clinical data (paper and electronic) will be kept confidential, will be kept secure, and 
will not be made available to any party other than the research team without the consent 
of the Individual subjects. 
• The potential risks to subjects of blood collection are minimal and are related to 1) blood 
sample collection technique, and 2) the volume of blood collected prior to racing and the 
potential risk of a decreased performance in the race. The potential risks associated with 
blood collection technique from the ante-cubital veins are: infection, delayed healing, 
haematoma, physical pain, mental discomfort and injury to a nerve or a vessel. These 
risks are small and will be minimized by the use of trained phlebotomists, use of sterile 
techniques and the use of disposable, single use materials. The risk of decreased 
performance as a result of blood collection will be reduced by not subjecting any 
participant to the collection of a blood volume exceeding 15ml prior to the race. 
• Body weight will be measured using a standard electronic scale, and there is no risk 
associated with this procedure. 
• The risks associated with participation in this component of the study do not exceed the 
risks associated with competing in the Ironman competition. The administration of IV 
fluids will involve an invasive placement of an intravenous line. The risks associated with 
the placement of an intravenous line include: infection, delayed healing, haematoma, 
physical pain, mental discomfort and injury to a nerve or vessel. These risks will be 
minimized by the use of trained phlebotomists, sterile technique and disposable, single 
use materials. If at any time the condition of a collapsed triathlete deteriorates, the most 
appropriate treatment will be Initiated, the trial terminated and the patient will be 
transported to the local hospital if necessary. The support form the local hospital is part of 
the normal standard medical care aSSOCiated with this event. 
Potential benefits of this component of the study 
• The data collected in this component of the study will aid in the development of optimal 
treatment strategies for collapsed triathletes. Although intravenous fluid replacement is a 
common practice in the treatment of collapsed triathletes, medical personnel need to be 
advised of a more judicious approach to treatment as to avoid the deleterious effects of 
fluid overload (hyponatraemia). This information will aid in the understanding and 
management of serum sodium disorders in collapsed triathletes by scientifically 1) 
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evaluating the efficacy of intravenous versus oral rehydration and 2) assessing if the 
normalization of serum sodium levels are important in the recovery of collapsed 
triathletes. 
Component 2: A study to determine the cause of Exercise-Associated 
Muscle Cramping (EAMC) 
General information 
The purpose of this component of the study is to determine the possible cause of exercise-
associated muscle cramping (EAMC) in endurance athletes. At registration. triathletes will be 
given the opportunity to volunteer to participate in this component of the study. 
Details of the study are as follows: 
• Prior to or at registration, a questionnaire detailing personal particulars, medical 
information, training information, and history of muscle cramping will be completed. 
• At registration, a blood sample (Sml - 1 teaspoon) will be collected from the vein in the 
arm using standard procedures. 
• Body weight will be determined at the time of registration, and on the moming before the 
race starts by stepping onto an electronic scale 
• Should you develop muscle cramping during or immediately after the race, and if you 
agree to participate, you will be admitted to a designated area of the medical facility at the 
finish of the race. 
• At the finish your core body temperature will be measured using a rectal thermometer. 
This procedure will take place in privacy, and entails placing a thermometer in the rectum 
(backside) for about 3 minutes. This procedure may be associated with mild discomfort 
but no pain. Normal precautions will be taken to ensure that the thermometer is clean and 
properly lubricated. Trained medical staff will perform this procedure. 
• Disposable surface patches (electrodes) will be attached to your cramping muscle/s and 
also to your arm (back of the arm on the triceps muscle) to record the electrical activity of 
the muscles. This procedure is not associated with any pain or discomfort. 
• During the time of your admiSSion to the medial facility you will be treated for cramping 
using standard accepted medical procedures. 
• You will be asked to stand and walk periodically (every 1Smin). unless you are still 
actively cramping. Once you are able to stand and walk with no cramping. you will be 
discharged from the medical facility. 
• Should you develop any medical complications or if your condition deteriorates. you will 
be treated according to normal accepted medical practices. and this can include 
admiSSion to hospital if required. 
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Potential risks of this component of the study 
• The completion of a questionnaire is not associated with any risk. Questionnaire and 
other clinical data (paper and electronic) will be kept confidential, will be kept secure, and 
will not be made available to any party other than the research team without the consent 
of the individual subjects. 
• The potential risks to subjects of blood collection are minimal and are related to 1) blood 
sample collection technique, and 2) the volume of blood collected prior to racing and the 
potential risk of a decreased performance in the race. The potential risks associated with 
blood collection technique from the ante-cubital veins are: infection, delayed healing, 
haematoma, physical pain, mental discomfort and injury to a nerve or a vessel. These 
risks are small and will be minimized by the use of trained phlebotomists, use of sterile 
techniques and the use of disposable, single use materials. The risk of decreased 
performance as a result of blood collection will be reduced by not subjecting any 
partiCipant to the collection of a blood volume exceeding 15ml prior to the race. 
• Body weight will be measured using a standard electronic scale, and there is no risk 
associated with this procedure. 
• All medical conditions, including EAMC, will be treated appropriately, based on the 
current standard of care or evidenced based paradigms. If at any time the condition of a 
triathlete with EAMC deteriorates, the most appropriate treatment will be initiated, the trial 
terminated and the patient will be transported to the local hospital if necessary. The 
support form the local hospital is part of the normal standard medical care associated with 
this event. Surface electrode placement and measurement of EMG activity is not 
associated with any known risk to the subject. 
Potential benefits of this component of the study 
• The antiCipated benefits of this component of the study are that the results will further our 
understanding of the possible cause/s of EAMC in endurance athletes. In particular, once 
the aetiology of EAMC is better understood, this will improve our ability to prevent this 
condition, and to treat it effectively if it does occur. 
Component 3. A study to determine the cause of post-exercise upper 
respiratory tract symptoms 
General information 
Upper respiratory tract (URT) symptoms such as a sore throat, runny or blocked nose, and 
throat irritation are particularly common in ultra distance athletes including triathletes. These 
symptoms occur mostly in the 2 weeks after a race. It has been shown to occur in 30-50% of 
all athletes after endurance events. It is important to understanding the relationship between 
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exercise and URT symptoms as it is known that infections have potential negative effects for 
the athlete. Having an infection or not may mean the difference between being able to 
compete safely, performing at a sub-optimum level at risk, or missing the event altogether 
because of illness. In recent years we have become aware that the symptoms of URT 
infections that endurance athletes suffer from after a race may NOT be caused by an 
infection. Instead this may reflect an irritation of the inner cell lining of the nose and throat due 
to allergy or perhaps pollution. However, we still need more evidence to prove this. 
The aim of this component of our research is to determine if the symptoms experienced by 
athletes after an Ironman race are due to an infective cause (microbial agent such as a virus 
or a bacteria) or due to a non-infective inflammatory process in the upper respiratory tract. 
The study will involve recruiting in excess of 120. triathletes who participate in the Port 
Elizabeth IRONMAN endurance race. You will be requested to report to a specific area at the 
registration desks in the 3 days prior to the event. At this time you will be asked to complete a 
questionnaire, and have a blood sample taken from your vein in the forearm. In addition nasal 
and throat swabs will be taken and you will be required give a specimen of your saliva (spit). 
Immediately after you finished the race, you will be asked to report to a specific section of the 
medial tent at the finish, where a further blood sample and saliva sample wi" be taken. 
You will then be asked to be available for a follow up in the 14 days after the race. Follow-up 
will take place in four cities (Cape Town, Port Elizabeth. Durban and Gauteng).You will be 
required to complete a short symptom chart every day, and you will be contact regularly 
(every 2 days) by a member of the research team to obtain this information. Should you 
develop any symptoms of upper respiratory tract irritation (such as blocked nose, runny nose, 
sore throat. cough) you will be asked to report to a research centre in the city (as mentioned 
above). There wi" be no financial compensation to attend this centre. but the medical 
consultation will be free of charge. During that visit you will be seen by a doctor, who will take 
a medical history. and conduct a medical examination of your upper respiratory tract (ears, 
nose throat and chest). In addition a blood and saliva samples will be taken. You will receive 
treatment and advice for the management of these symptoms. 
Potential risks of this component of the study 
• The completion of a questionnaire is not associated with any risk. Questionnaire and 
other clinical data (paper and electronic) wi" be kept confidential, will be kept secure. and 
will not be made available to any party other than the research team without the consent 
of the individual subjects. 
• The potential risks to you during blood collection are minimal and are related to 1) blood 
sample collection technique, and 2) the volume of blood collected prior to racing and the 
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potential risk of a decreased performance in the race. The potential risks associated with 
blood collection technique from the ante-cubital veins are: infection, delayed healing, 
haematoma, physical pain, mental discomfort and injury to a nerve or a vessel. These 
risks are small and will be minimized by the use of trained phlebotomists, use of sterile 
techniques and the use of disposable, single use materials. The risk of decreased 
performance as a result of blood collection will be reduced by not subjecting any 
participant to the collection of a blood volume exceeding 15ml prior to the race. 
• The potential risks associated with the collection of saliva and throat swabs are minimal. 
Local minimal and transient discomfort in the upper respiratory tract is the only anticipated 
risk. The collection procedure will be conducted by trained staff. 
Potential benefits of this component of the study 
• The anticipated benefits to subjects participating in this component of the study are firstly 
that the knowledge of the cause of the symptoms of the URT after an endurance event 
will be known, secondly that the treatment of these symptoms will be based on sound 
scientific and clinical evidence and finally, that triathletes can be given accurate and safe 
advice on training during the recovery period. 
Component 4: A study to determine the genetic basis for performance 
and physiological responses during an Ironman Triathlon 
General information 
A study to determine the genetic basis for performance and physiological responses during 
an Ironman Triathlon will be conducted by the UCT/MRC Research Unit for Exercise Science 
and Sports Medicine at the University of Cape Town in Cape Town, South Africa, in 
conjunction with the Molecular Genetics Department B and Laboratory of Forensic Genetics 
of the Cyprus Institute of Neurology and Genetics in Nicosia, Cyprus. 
The study involves donate ten millilitres (2 teaspoons) of venous blood and this will be done 
at race registration and after the race (five millilitres - 1 teaspoon). Five millilitres of the 
sample will be used for the extraction and analysis of genetiC material (DNA), while the 
remainder of the sample will be used to measure serum electrolyte (salt) levels. In addition, 
body weight will be measured prior to the start of the race and again in the medical tent on 
completion of the race. 
The DNA will only be used for scientific research purposes relating to the genetiC basis of (1) 
athletic ability, (2) tendon and ligament overuse injuries and (3) dysnatraemia during ultra-
endurance events. Personal particulars and sporting and medical questionnaires will have to 
be completed and this information will be treated with the strictest confidentiality and will only 
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be used for scientific research purposes. All data will be analysed anonymously and DNA 
samples will be destroyed on completion of the study. 
Part of the DNA extracted form the donated blood sample will be sent to the Cyprus Institute 
of Neurology and Genetics in Cyprus for analysis. DNA samples will be shipped to and 
analysed in Cyprus anonymously. DNA will be genotyped (analysed) for variations 
(polymorphisms) within genes relating to the genetic basis of athletic ability, tendon and 
ligament overuse injuries as well as water and salt imbalance during ultra-endurance events 
only. 
Potential risks of this component of the study 
• The completion of a questionnaire is not associated with any risk. Questionnaire and 
other clinical data (paper and electronic) will be kept confidential, will be kept secure, and 
will not be made available to any party other than the research team without the consent 
of the individual subjects. 
• The potential risks to you during blood collection are minimal and are related to 1) blood 
sample collection technique, and 2) the volume of blood collected prior to racing and the 
potential risk of a decreased performance in the race. The potential risks associated with 
blood collection technique from the ante-cubital veins are: infection, delayed healing, 
haematoma, physical pain, mental discomfort and injury to a nerve or a vessel. These 
risks are small and will be minimized by the use of trained phlebotomists, use of sterile 
techniques and the use of disposable, single use materials. The risk of decreased 
performance as a result of blood collection will be reduced by not subjecting any 
participant to the collection of a blood volume exceeding 15ml prior to the race. 
Potential benefits of this component of the study 
The antiCipated benefits of this component of the research study are to identify genetiC factors 
that may predispose to 1) improved performance or 2) increased risk of medical 
consequences (such as abnormal electrolyte imbalances). This information will eventually 
assist triathletes in predicting and improving their performance, and decrease their risk of 
medical complications during participation in triathlon. 
Component 5. A study to determine the genetic riskls associated with 
chronic Achilles tendon Injuries in triathletes 
General information 
The purpose of this component of the research study is to determine if there are specific 
genetiC factors (refer to the details for component 4) that are associated with the development 
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of chronic tendon injuries. In addition, we want to determine what the effect of an endurance 
event (such as the Ironman) is on the structure of the Achilles tendon. 
At registration you will be required to complete a questionnaire with personal details, training 
details, past injury details, and details about family history. In addition, a 5ml (1 teaspoon) 
blood sample will be taken from a vein in your arm. Finally, a qualified radiologist will examine 
both you Achilles tendons using a soft tissue diagnostic ultrasound machine. This procedure 
entails putting a clear jelly on your skin, and then using a probe to examine the tendon by 
passing it over the skin. This is not associated with any discomfort. 
After you complete the race, you will be asked to undergo the same procedure (blood 
collection and ultrasound examination) in the medical facility at the finish. If possible, you will 
be asked to report to a medical centre close to your home for a final ultrasound examination 
approximately 6 weeks after the race. The cost of this will be free, but you will not receive any 
financial compensation to attend this centre. 
Potential risks of this component of the study 
• The completion of a questionnaire is not associated with any risk. Questionnaire and 
other clinical data (paper and electronic) will be kept confidential, will be kept secure, and 
will not be made available to any party other than the research team without the consent 
of the individual subjects. 
• The potential risks to you during blood collection are minimal and are related to 1) blood 
sample collection technique, and 2) the volume of blood collected prior to racing and the 
potential risk of a decreased performance in the race. The potential risks associated with 
blood collection technique from the ante-cubital veins are: infection, delayed healing, 
haematoma, physical pain, mental discomfort and injury to a nerve or a vessel. These 
risks are small and will be minimized by the use of trained phlebotomists, use of sterile 
techniques and the use of disposable, single use materials. The risk of decreased 
performance as a result of blood collection will be reduced by not subjecting any 
participant to the collection of a blood volume exceeding 15ml prior to the race. 
• Soft tissue diagnostic ultrasound is a well described and common clinical diagnostic 
procedure that is associated with no known risk. This procedure will be undertaken by a 
trained radiologist. 
Potential benefits of this component of the study 
• The antiCipated benefits of this component of the study are that the results will clarify why 
certain triathletes may be more or less prone to chronic tendon injuries, based on their 
genetiC make-up. In future, this work may lead to the screening and early identification of 
an increased risk for tendon injuries. so that preventative measures can be undertaken. 
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Component 6: A study to determine the relationship between training 
history, perception of effort during the race and the subsequent 
recovery after the race 
General information 
The purpose of this component of the study is to investigate whether the strain experienced in 
the recovery period after an Iron man is directly proportional to the perception of effort and 
racing intenSity in a group of similarly trained triathletes. The answer to this question has a 
practical application for training and also contributes to a better understanding of the 
physiological responses of ultra-endurance events. 
The research project will involve the following: 
• About 1 week before the race you will be asked to complete a questionnaire on your 
training habits for swimming, cycling and running in preparation for the Ironman and your 
personal best times for the 3 disciplines. This will take about 30 minutes. 
• You will be familiarised with the subjective scores for "perception of effort rating" and 
"pain assessmenf' before the race. 
• During the race researchers will be allocated to about 12 stages throughout the race. As 
you swim, run or cycle past these researchers they will hold up two boards with the 
scores for "perception of effort rating" and "pain assessmenf'. You will be asked to shout 
out your respective scores as you go past them and they will record these scores against 
your race number. 
• You will be sent an email on a daily basis for a week after the race with a short 
questionnaire on your subjective perception of recovery. This questionnaire will take 
about 2 minutes to complete. Thereafter, you will be sent an email on a weekly basis for 
12 weeks with the same short questionnaire. 
• Blood samples after the race will be obtained 1, 3, 5, 7 and 9 days later for the 
measurement of creatine kinase. 
Potential risks of this component of the study 
• The completion of a questionnaire is not associated with any risk. Questionnaire and 
other clinical data (paper and electronic) will be kept confidential, will be kept secure, and 
will not be made available to any party other than the research team without the consent 
of the individual subjects. 
• The potential risks to you during blood collection are minimal and are related to 1) blood 
sample collection technique, and 2) the volume of blood collected prior to racing and the 
potential risk of a decreased performance in the race. The potential risks associated with 
blood collection technique from the ante-cubital veins are: infection, delayed healing, 
haematoma, physical pain, mental discomfort and injury to a nerve or a vessel. These 
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risks are small and will be minimized by the use of trained phlebotomists, use of sterile 
techniques and the use of disposable, single use materials. The risk of decreased 
performance as a result of blood collection will be reduced by not subjecting any 
participant to the collection of a blood volume exceeding 15ml prior to the race. 
• Data for this component of the study will involve contact with subjects during the race. 
There is a potential risk that in the process of data collection, the performance of subjects 
in the race will be interfered with. This risk will be minimal, as the nature of the data 
collection is such that subjects will only be asked to shout out two numbers as they pass 
members of the research team at designated points in the race. However, should 
triathletes feel that this affects their performance during the race, they will be free to 
withdraw from this component of the study. There will be no interference with other race 
participants during this data collection process. 
Potential benefits of this component of the study 
• The anticipated benefits of this component of the study are firstly that subjects will receive 
a full summary of their individual results, as well as the overall findings from this 
component of the study. Secondly, and more specifically, the individual results will include 
information about their training and development of fatigue during the race which will be 
of interest. Finally, these results may assist triathletes in modifying their training to 
improve their performance. 
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Appendix 3: Informed Consent Form 
THE PORT ELIZABETH IRONMAN TRIATHLON 2006: 
MEDICAL CONSEQUENCES FOLLOWING ENDURANCE 
SPORTS RESEARCH PROJECT 
I, , agree voluntarily to participate in the 
UCT/MRC Research Unit for Exercise Science and Sports Medicine's research 
project with the following components titled:-
• "A study on the management of the collapsed triathlete", 
• "A study to determine the cause of Exercise-Associated Muscle Cramping 
(EAMC)", 
• "A study to determine the cause of post-exercise upper respiratory tract 
symptoms", 
• "A study to determine the genetic basis for performance and physiological 
responses during an Ironman Triathlon", 
• "A study to determine the genetic riskls associated with chronic Achilles 
tendon injuries in triathletes", 
• "A study to determine the relationship between training history, perception of 
effort (RPE) during the race and the subsequent recovery after the race", 
performed by the University of Cape Town and the Sports Science Institute of South 
Africa. I have read the subject information sheets and the following procedures and 
concepts have been explained to me in full: 
1. Completion of a questionnaire: The completion of a questionnaire is not 
associated with any risk. Questionnaire and other clinical data (paper and 
electronic) will be kept confidential, will be kept secure, and will not be made 
available to any party other than the research team without the consent of the 
individual subjects. 
2. Blood sample collection at registration. immediately after the race. and if required 
in the 14 davs after the race: The potential risks to subjects of blood collection are 
minimal and are related to 1) blood sample collection technique, and 2) the 
volume of blood collected prior to racing and the potential risk of a decreased 
performance in the race. The potential risks associated with blood collection 
technique from the ante-cubital veins are: infection, delayed healing, haematorna, 
physical pain, mental discomfort and injury to a nerve or a vessel. These risks are 
small and will be minimized by the use of trained phlebotomists, use of sterile 
techniques and the use of disposable, single use materials. The risk of decreased 
performance as a result of blood collection will be reduced by not subjecting any 
participant to the collection of a blood volume exceeding 25ml prior to the race. 
3. Measurement of body weiqht before and after the race: Body weight will be 
measured using a standard electronic scale, and there is no risk associated with 
this procedure. 
4. Treatment if I collapse after the race: (only for the collapsed athlete 
component) If I collapse during or after the race I might receive either IV (drip 
into arm vein) or oral fluids ad libitum (as much fluid as I want). I will be attended 
to in a separate section of the medical tent under the supervision of a qualified 
doctor. I will be assessed regularly (every 15 minutes) and I understand that 
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optimum care will be provided to me according to the current standard of care. 
Treatment will cease when I am alert, oriented, able to walk and when my 
laboratory tests are normal. I will be transported to the local hospital if my 
condition requires more urgent medical attention. 
5. Treatment if I develop muscle cramps during or after the race: (only for the 
cramps component) If I develop muscle cramps during after the race I will 
receive treatment in a designated area of the medical faCility. Optimum care will 
be provided to me according to the current standard of care. I will be required to 
have a rectal temperature measurement taken, blood samples will be collected, 
body weight will be measured, and I will have surface electrodes attached to my 
muscle to measure electrical activity. Treatment will cease when my cramps have 
stopped and I am able to stand up and walk. I will be transported to the local 
hospital if my condition requires more urgent medical attention. 
6. Saliva sample collection at registration. immediately after the race. and if required 
in the 14 days after the race: (only for the URT component) The potential risks 
associated with saliva sample collection are very small. I may experience 
transient discomfort as the inner lining of my throat is swabbed with a soft swab. I 
understand that all the normal precautions will be taken during this procedure, 
and that it will be undertaken by trained staff. 
7. Assessment and treatment of symptoms of the upper respiratory tract in the two 
weeks after the race: (only for the URT component) I understand that should I 
develop any symptoms of the upper respiratory tract in the 14 days after the race, 
I will be required to report to a research centre in my home town, to be examined 
by a doctor, give a blood sample and have a throat swab as well a saliva sample 
taken. I understand that I will then be treated for my symptoms according to 
standard medical practice. I understand that I will not receive any financial 
compensation to attend the centre. 
8. Soft tissue diagnostic ultrasound examination: (only for the Achilles tendon 
component) I understand that I will be subjected to a soft tissue diagnostic 
ultrasound examination of my Achilles tendons during the registration period, on 
completion of the race, and if possible 6 weeks after the race at a medical facility 
close to my home. I understand that I will not receive any direct financial 
compensation to attend this centre for the ultrasound, but that the investigation 
will be free of charge. I understand that these investigations are not associated 
with any risk, and will be performed by a trained radiologist. 
9. The genetiC basis for performance and phvsiolooical responses during an 
Ironman Triathlon as well as to determine the qenetic riskls associated with 
chronic Achilles tendon injuries in triathfetes: (only for the genetiCS 
components) These components of the study are been performed in conjunction 
with the Molecular Genetics Department B and Laboratory of Forensic Genetics 
of the Cyprus Institute of Neurology and Genetics in Nicosia, Cyprus. At race 
registration, I have agreed to donate ten ml (2 teaspoon) of venous blood. Half 
the sample will be used for the extraction and analysis of genetic material (DNA), 
while the remainder of the sample will be used to measure serum electrolyte 
(salt) levels. I also agree to donate an additional five ml (1 teaspoon) of venous 
blood after the race in the medical tent which will be used to measure post-race 
serum electrolyte (salt) levels. 
The DNA will only be used for scientific research purposes relating to the genetiC 
basis of (1) athletic ability, (2) tendon and ligament overuse injuries and (3) 
dysnatraemia during ultra-endurance events. I also understand that all data will 
be analysed anonymously and my DNA sample will be destroyed on completion 
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of the study. I understand that some of the DNA extracted form the donated 
blood sample will be sent to the Cyprus Institute of Neurology and Genetics in 
Cyprus for analysis. I understand that the DNA samples will be shipped to and 
analysed in Cyprus anonymously. I understand that the DNA will be genotyped 
(analysed) for variations (polymorph isms) within genes relating to the genetic 
basis of athletic ability, tendon and ligament overuse injuries and dysnatraemia 
during ultra-endurance events only. 
I understand that whilst there is no direct benefit to myself, if a genetic 
predisposition for (1) athletic ability, (2) tendon and ligament overuse injuries and 
(3) dysnatraemia during ultra-endurance events can be established, then future 
generations will be able to establish their risk for this condition. This may allow 
better prevention and treatment options in the future. I understand that I will 
receive the overall results of the study. 
I have read (or, where appropriate, have had read to me) and understood the 
information about this study, and any questions I have asked have been 
answered to my satisfaction. I agree to participate in the study, realising that I 
have the right to request that my DNA sample be destroyed at anytime. I agree 
that research data provided by me or with my permission during the project may 
be included in a thesis, presented at conferences and published in journals on the 
condition that neither my name nor any other identifying information is used. 
10. Providing information on my rating of effort and fatigue status during the race: 
(only for the RPE component) I understand that I will be required to study and 
familiarize myself with two scales of perceived effort and fatigue before the race 
starts. I understand that during the race, at designated stages, I will be required 
to report (by shouting) my perception of effort and fatigue to members of the 
research team. 
I have read the preceding subject information sheet and understand the testing 
procedures outlined therein. I understand any accompanying risks and discomforts. 
Knowing these risks and discomforts and having had the opportunity to pose 
questions answered to my satisfaction, I hereby consent to participate in this study. I 
understand that I may withdraw from this study at any time without further question. I 
have been informed that the individual data derived from my participation in these 
protocols will remain confidential. I understand that the medical staff and the 
research team have professional medical insurance. 
Name of the triathlete: 
Signature of triathlete ___________ _ 
Date: 
Name of investigator: _Prof Martin Schwellnus __ _ 
Signature of Investigator: 
Date: 
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Appendix 4: 2006 Ironman Medical and Training 
Questionnaire 
Department of Human Biology 
UCT/MRC RESEARCH UNIT FOR EXERCISE SCIENCE & SPORTS MEDICINE 
Faculty of Health Sciences, University of Cape Town 
Private Bag, Rondebosch 7700. South Africa 
Tel: + 2721 6504561 
Fax: + 27 21 686 7530 
2006 IRONMAN - MEDICAL AND TRAINING QUESTIONNAIRES 
These questionnaires have been constructed by the Medical Research team, in 
conjunction with the Medical Director of the Ironman 2006. The infonnation obtained from 
the .. questionnaires Is essential for the planning of medical care during events such as 
the Ironman 2006. We acknowledge that the questionnaires are long, but we are asking 
about 20 minutes of your valuable time to complete them. The completion of the 
questionnaires is voluntary, all the infonnation will be kept confidential and will only be 
used for research and medical care planning purposes. We suggest that you consider 
completing this before the event, or at the time of registration. 
Prof Martin Schwellnus (Chainnan, Research Team) 
Dr Peter Schwartz (Medical Director, Ironman 2006) 
Instructions 
You can either complete the questionnaires electronically using Microsoft word or print the 
questionnaires and complete them manually. Please answer each question by filling in the 
details in the allocated space or checking one or more of the option boxes. 
If you complete the questionnaire electronically using Microsoft word, please e-mail the 
completed forms to ironman@sports.uct.ac.za and bring the signed consent form to the research 
table at race registration. 
If you complete the questionnaire manually, please bring the completed forms together with the 






Please complete sections A, B, C, 0 and E 
Personal Details 
Racing, Training and Equipment Use History 
History of Medication, Supplement and Fluid Use as 
well as Lifestyle and Habits History 
Family Medical History 






Please complete only the relevant questions In the following section 
Section F Additional Detailed Medical History Pages 11 ~21 
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Sect ion A : Personal detaU, 




PostaV z,p Code 
E-mail address Phone (da, time) =. '" 
Dare of birth I'VVY- " , 0" Cell 
He"lhl = Gender ~'a:e 0 Female 0 
Welghl <9 "'. I 
EthnIC group BlackiAfrican 0 Whte Ind,an 0 (Only Requtred and 
Used lor Research 
Purposes) Mixed Ancestry (Coloured) 0 Asoan 0 Other 0 
Arocestry Tntnll or 
0 nal lonal rathe r- Unknown 
~9roUl1d 
(ey Xhosa Outer. 
0 ZUI U~n~rman . Mo:her- Unkn<,lwn 
Italian 
Country of Birth 
Dommant Hand Left 0 Right 0 Bo:h 0 I Oomlnam Leg I Left 0 Righi 0 Both 0 
Occupa~Ofl 
I ::;:~=. 
Si" ing , 
Standing --• 
Walkong (Lower t>ody adlvity ) --• 
" Manual Labour (upper and body actIVIty) • 
Section B. Racing and train ing history 
S""d~ rd 
Type of tri~tht on Sprint ,U,". ") II. tronm~n tronm~n 
'Much lr1alnlons have)'OO 
Yes 0 NoD Yes 0 NoD Ye~D NoD YesD NoD ~t ' In? 
Yearol~rmevenl 
~.a.:'~ eVfO~l~ have you 
,,? 
'6ii , ,-, 
~ hrs:m,n 
, hrs.mln , 
I ~! y<lur "me for your 
t race dUring the hrs·mrn hrs·m,n II rs min IIrs:m,n 
I pal 12 monlhll1 
evenl "m - " .Hm ... , km 
INtI"" races nave you ever Yes D No[] Yes D No[] yesD NoD Yes DNo[] , 
Year 01 f'lsi evenl 
events have you 
~~ _ hrs min , , , ,: 
hrs min hrs min hrs:m ,~ hrs min 
~ 




Yes D NoD YesD NoD 
Yeal of ~fst evenl 
f~ 
hav9 you , 
hrs:mm 
\'llhiliis your oost average cyc ling speed (kmlh) In Average speed -- )"'" 
a filce over 80 km on thfO lUI 15 weeks 7 D'S:arlCe 1m 
Whal IS yOlJr best slWI1ml'lg permrmaO>(:e In the ,,~ --- m" 
lUllS weeks? D.s:ance m 
Enllre eVfOnt min ---
What IS yOlJ r pmdICted time for IhfO enllre 2006 Sw.m --- m., 
llooman everl an<! each of tn!! Ihre!! sPIllS? CyCle --- m" 
RufJ: m" 
" , ., " 
, 
t 15 weeks I... ~ 
1 day!l a ... eek dod you traon ~ dav,.lweek 
'Mm ~m/ ... ~ 
you train m an iI'Ier~e week dunng the 1~5t C,.. :un 'w""'~ 
,", ~,.... 
'.rn hrs.\Neek 




you Ira,n In the week !)ela,e the raee? C>d. -- ~ 
Run. "m 
'wm ""''' --I dkl you l!lIm in II>e wuk btlQr. the race? Cycle. -- ""'" ,", ""'" --
Flexibility training history 
~'~ ~D N'D 
If YES. pleaH CQmp:e:a the resl oTh IleJub,ijly h'alnO'llg ~ story sec\IOI1 below-
II NO. CQ(!1.nuacompletl"9 the qUH~onnaua!rom:he lop rJ page 
~ 
,how many dayi • ..... do you ~oon a ,.:retCh.ng daY5Jweek 
-
~ 
• Ilrt!CI\Ing I,me!lo'day 
, , 
Piease \IC~ .,.,.,!ch muiOt gfOUpS do yOu Include 
=l' .n your stretch,ng seulO~? (inn e< 1M gM) 
~bOdY hmb$ 
Please tid; wlle<1 you slretd1? 1!Je/OO'e dunl'\! and/or efteo' ~ 
e~I!fClslJ\Q You can to;. moretllan ore bo. , ~~erCl$e 
W- an moMduaI mu8de Il'oup. on average. "'" seconds , ''''' qo;;;;-
, 




PIeMo 1OdIe8I& wtueh 
04 bicycle you 
Please II'!<1ICaIe wtuch 
l)'Peat handi, bars "" ~, 
Please Indicate whICh 
Please Ir'docal& wIllcf> 
type of cycllna .lIom 
~, 
P~ase IndlCBlD wnlCh 
type 01 cycling slto., 
""-' 
Plea5/: lI'\d,cate which 
type ~ !ill YO\I use? 
Please If'doc:ale .... hoel> 
b.lInd 01 funning 
Plea:;e Irldx:ata wM;:h 














Selle San Marco· !Wwr p ,orJ 





"" "", Zoo, 








Section C. History o f medication and supplement use 
Name of medlCClbcln 'f ",an; taken 
What medlCallon. ,I any. are you 
currenliy usmg? (please list) 
Do you use prOlechW slvn 
Yes D NoD 
o Every sessoon o Most sessions 
sunscreen dur,ng lr<l,llIng o Some sessoons o V .. ", occask>na~y Session Of when compel"'g? 
Are you currently taklrljj dietary supplemenlS/Vitamlns? IYesDNo D 
Name 01 supplement I 'fears taken 
I ~ Multi-Vitamins --o Anti-oxidants --
If yes to the above question, 
o Immuoe boosters --
please list names 01 d.,tary o Prole,n powders/supplements. PrOle;" bars BCMI - -
sports or Vltam,n supp:E!mtlnls o Creatine --o Caffe",,,, --o Fat cullers o Carbohydrate drinks/powders/gels - -
DOrner· 
Have you ever u!;ed oral 
YesDNo D 
03 m1Ylths 06 months 
cortICOsteroids (carMone o 12monlhs o 24 Of more monlhs ~etsl? (11 yes how long ago?) 
Have you eve' been given an 
Yes D NoD 
0 3 months 06 monlhS 
injedlQn Wllh cortICOsteroids? (11 o 12monlhs 024 or more monthS y .. how long ago?) 
Have you eve. been given an 0 ""'" o Twice iflIt'C1'On of cort«;osteroods ,n or 
Yes D No D around tMe Achilles tendon? (I I o 3 l imes 0 >3 times 
y .. how many t.mes?) 
Halle you eve. used 
YesD NoD 
0 3 months Os monlhs 
I luorDqu'oo llne antlblotocs? (.eler 
0 12 months o 24 or more mooths 10 lne loIIo'M list) 
~t 01 some fluoroquinoline antibio tics; 
ADCO-CIPRIN CIPR.OBAY SANDOZ CIPROFLOXACIN 
AVELON CIPROGEN TAFlOC 


















Lifestyle and hab its h istory 
Plaasa ,n<! eatll yo~r $IlIoI< . .,; 
C~rrenl smoker D ,,-"smoker 0 Never smoked D StilWS 
It ycv 8OS"ered Number oi year, of $IlIOk<ng I lf SiOllpOO. hOW many years ago 
yes, (paS\ QI 
curronl smoker) 
pl~se ccmp/fl1O 
What II (wasl meav(I(ogo ..... mber cI ogarllt1e5 pC! ca~ thll socl>Qn Qf1 !hll 
rlghl 
glasSEl5 OOeriCNI8f per week 
0rI average how mud'! alcohol dO you (lnnk per wee!<. 
gtallleS w' ne per weol< J ltots g.asses)oI$pIn\s ..... r>eQlboer7 lOll 0( sp"<ts per wool< 
Fluid tnlllke 
(a) I dnnk 10 IIWSI 
HQw (10 yQO,l 00s1 (b) I dnnk as much al 1~llI'ab'e 
()ew'De ycur ~UKl (~) I drjn~ accord,ng 10 8 plOOelerm,ntod nuid inlake 5<:tHld~1e 
Intake dlmnglln (d) I OMk 10 pr~enl any w~gnlIQU ouring exerCIse 
Ironman InathlOll (Il) I comlJ>l10 (3) w,1n (e) 
~, 
(f) I comb.ne (b) With (e) 
(g) OIlIer 
Waler 00.25"" 0 26-50% B 51-75% 071).100'II. 
Whilt percentage or Sports dronk B 025'!1. § 26-50% 51·75'lrt B 71).100'II. yotJr flu", 'ntake .... 
Co<. 0.25% 26-51% 0 51.75'lrt 16-100'W0 CQf\Stf\ of !h1lS1l -' om. 00.25'" 26-50'" 0 51.15% 071).1~ Spocdyom..-Whal I0Il oeyour OShmattIG !QYl 'k,,,d ,nta~e be (If II I II ) e!YMgthe swlm? ml 
\'VMC"'" bo your OSl!f11aleG 101,1 rou,e! Inlake be curmg 1M ll£.!!? ml 
What.....,~ be your OSMlated t2!! !.Jluld Intake be dunng the!l!!1' ml 
Rani< 1M loIlQ'M1lQ -- Fellow jria lnilltes 
sourcelol lnlormallon --Coach itra lner 
011 metr Importance irI _ _ Magazmes l !:<IOks 
1000000lalll'lll your __ Webs"e (please Spac,fy I 
onnkmg slralegy (1 
DfLn~"'9 gurdel'n(!1 from apQrlS .SSOOailOns bel'lg moll ,~~uent.al 
a~a the to ..... esl Aovef1s 





Hive .ny of your blood (blologlc.,) rel.llvn!tt! hi d the following? 
PieHl tick yes or nO. II yes. pl,ne tick Ille rellil ionship or thai person to you (You m.y lick 
mo,. thin one 01 the re'atlon,hlp bloch). 
01 , ... ; 01" ; 
~ E~efc;l!e-ass.oda ted museJe vesDNoD $lste< 
" -'" , 
YesDNaD 
:J; ~~""' 0. N gMI musClo crampi SISter 




I~'·: [jI, " rupwre VeiONOO , 
~ 0., YesONoD :r. 50Sler 
"i 0, , 
Aslhma veiDNoD ~,. Ie". 
~ 0., Alle<g'e5 ( .. genefal) YesDNoD 50S'. 
:J; t 0. vesDNoD Heart Dlseas" S'5let 
~ ..... vesDNoD SISler 3~:· 0, , 
Section E. Personal general medical history 
In this section. you aro ukod 10 .ead through 14 queshons aboul you. pe.sonal general m"dical 
history . II you anSWer hyesh to any 01 questions 110 12, please complete Ihe additional qu.,,;llons 
at the end olthe section (sec tion F On page 1 t ). 
, , did you suffer Irom any 
blocked or .Utlny nooe. cough. wheeze 
2 HilVe you ~ In trl~t1l10n career suffereD 
Immedliltely (within 6 hourS) a!ter e~erose (I 
I your trialhlan career 
5~H'ne5S) on 
) I I j 






ll. nausea I pain. urge 10 Yes 0 No 0 
~~oodlnlhe;~;i~::~~~;;i";;;'=--jl-::::;:;::-;=;--j , In you. lrl8lhlon career suffare<i I.a.,:, ~ymp(()fl1S of t~ nervous 




a Hav" you n!! In your Inalhlan career Sulle.cd lro<TI 
Ir>dudlrtg n05e allergies IMy fe_e,). alrergic Som,J5I(S, 
allerg es a oast h<5tOl)' 01 allergies to medication. ~lant m;,~;"., " .m;" 
malenai? 
Do you currently su ff er !.om uthma Indi,KIlng exe rCIse Induced asthma. or 
symptoms of asthma such as shortIless 01 breath, wheezing or ctlfanic 
cough'"g? 
It I I 
because an accident 
or alte' a 
suffe. from any symptoms 01 in lury on [he muscles, tendons, 
Sunburn Yes 0 No 0 






UlIler sk in Damage resulting sun exposure. ym; 0 NO 0 
"5 
0 ... " o Fonger 
BNec~ o Lower back 
Face DHlp o Front eMSI o T high 
, 3 P~aM lICk on whoch ~flatorTHcal area o Back eMSt o Knee 
you over had \lu rgery performed o Snooldor a lower leg o Upper arm Acniles 
D EIOOw OM .. o Foroalm O'~ 
Ow"" 0 "",-o Olner (Speedy ) 
14 FIPfIl'" . Ihlet" onty: 
Please complele tile following quesbons (148 10 149 1 rel<lle<:llo YOVI menstrual cyc'E! and or"" 
,e.1 h"t';'" 
14i1 At Whal age did yOU start yOl" perIOds (menwua~ng)1 (yea,s) 
141) In !hllll! 12 mcnlM. IIo'N many menstrual eydfl did yoo I\IIve? 
14c Ha .... you eve!' h8d Itregular menstrual perIOdS In the pall? vos D No D (exd.K!lng pregl'\8nc:y)? 
14d Have you ~d iI ny5terectomylo~ilra<;lomy? vos D No O 
140 HOW many tImes Me'lil you tleen progrl8nt? (tomes) 
14[ Whal lorm 01 coolrscepllOf1 are you ON~ 
curre!llly lls<ng? o Oral CQI'lIfacepuve pd l o Injection o Im.a· .... erlne deVIce o SleollZ8!JQ(1 (lllOeslled) o ",""c 
B Not applicable 
"'-.",,'W 141 8~ for 2!iI! Dermalolog;cal 
~~r wnal re8!K11'1 was o COlllracepl1(ll'l o Regulate penOd 
o atner 
THANK YOU FOR COMPLETING THIS QUESTIONNAIRE 
I' you have answered YES !O any Of the first 11 questions of the Personal 
Genera! Medical History auesIJonnaollQw In section F 
If you have completed the QuesIJonnalre manually, please bnng the compJeted 
forms together With the S'9ned consent form to the research table al race 
regiStration. 
If you have compteted the QuestIOnnaire electronically uSing Microsoft word, 
ptease e-mallthecompletedformSlOlronman@spor1s.uct.ac.za and brmg the 
SlQned consent form 10 Ihe research table at race registration. 
"" 
Section F. Addllional detailed medical history 
(Please complete allllle sections to which yOIl answered " Yes " /n the Personal general medical 
history) 
1. Flu symptoms in the last6 weeks 
11 you answered YES 10 question 1 in section E please complete the lol lowlng two questIons related to 
nu symPtoms In the last 6 weeks 
B Fever o Cough o Joint pams 
(ta) Please t,ck wh,ch 01 these nIl Blocked nose o Wheezing 
symplOl1l$ you su!l!!!ed Irom in the o Runny nose o Muscle aches 
las! 6 weeks DAlly Olher fi u symPloms 
(Spooly I 
o Fever o Cough o JOint pams 
(1 til Please I ck whIch 01 these Ifu o Blocked nose o Whee~ ing 
symolOfTI$ you suffeled IfOm In the o Runny nose o Muscle aches 
last 1 days o Any olher ~u symploms 
(Spec lly· I 
2. I cramping 
I 'Ou answ~red YES to question 2 In seCMn E please complete Ihe follOWIng questIOns (23 102m) 
I 
".,1 years ha~e you SUr!!!ed 1m", cramping? (years ) 
(2b) Old you ~ ,.~ "<~U 
12c) I ~~~"your cram~ng o Swimming o Cycbng o Runrllllg 
~~,y • --'" Races 
, fI Traonlng seSSions '" '" "' '' IJI' 'II? -_. 
~ Stretch",!} 
, 
~!~e you hila Ihat Drinking flu id 
II II an acute cramp? Massa!}e , 
Sal! (tablets or solut;onj 
Other ISpeclly I 
121) At what point in the race or training First quarler 
~ ~~~p~ttern run do you usually '''st e~Denence Th lra quarter Clamporlg' Alter the race 
(291 In w~lc.h mU$cles do yOU Il~ual ly o Calves B Hamstrings 
cramp (",ease list Ihe muscle by tile one o Quaariceps (thogh) Foot mus<; les wh,ch Clamps rT"OSt frequently las 1] and o Olher (Specify I the othttrs aft~ thai (2-4)? 
(2h) Haye sulfe!ed from cramping '" ~our legs)? >0, J", [ 
1 2 ilHav~ I y" J,,[ 
, , , , 
'r'esDNo D 
, _ hao Md,rk u rine" In the 3 oays 10110"'''9'' crampong epIsode? 
, , 
~ 
, t~ , t I 
i21T' ) II you CfaTp how 3 ~~ <, ~OO,~ ,00 'w~, ,b<" <0'"""' " •• "'" 
Itt!!! ",;he erarT'P ~"y? . 5-15 mlOllles " no you 8fe eble 10 conW1\Je exerCIsing 
Ip/ease todl) >15 monules or if you r 
3 Put Tendon and Lig.mentlnjury HrslO<y 
II you ansWefed YES to qUHtion 3 ·n se<:bOI'I E p\!!ase compll!ll1 [he IoIlow,ng quest,OIls (38 10 3d I 
relsle<! 10 you r pMI hI5~DfY or teooOlll'gamem u.,ryl0f!5 , 
. :~I~ Please tICk oMlod1 
Tendon 
.,,,, 
~ I~~' " ""'" F 00\ and ankle poslenO!' 
AlSO tl'ld!C3l.8 (tICk) " Knee 
J~~011 0 0 yoor ,nlUll!<ltendon ElbOW and wrISt 0 0 was IOllQstandm9 PilOn 
Ite ndmop!ltlly) Of an 
Shoulder ...J ROt81Of roll U U acute tearlrupture , 0 0 
Ligament Sprain 
"' S;; 
I ~~t'c~ Wh·eh 
Elbow logamemt 
II t ~garNf11! 
Flng8f l igaments 
Knee (ACL) 
Kn ee (Mel) 
Abo ondICII18 ~ yaur Knee (pel) 
SPllllrIed or COlI"plel-'Y Knee IlCL). 
lore me I.g&mOOt I I l igaments 
ligaments , ligaments 
noo" 
, "')' "" 
Acute shoulder Il lslocauoo 
i2!!!! r;h",",~ <.h"'Jki.". "'~'Ah~I'y 
!~'-' "." , 
'" 
YnO ,, 0 (re'er to the I SI on the 
t I  (If yes. soooly· 
'" 
List of some Conneetlve TI .. u. endlor Rheumatic DI ....... nd DI.order. 
Ankyr....mg SpcndyilnS upoa SIOI. 0-.... '-A.lpa1yIgI~"· .. m. (AGUI M"""n S)'I1<IIome RellCl...,. Ar\!l,," 
B\thcols Syrldrorne MMOell(ri;y H.-S~ l'\e40(1 S)'II<Irome 
CrOl'<"o."""", Muco~ .. s RelapMg PoIyc;nrondm.. 
DIs<;ood wpuo E<ytt>ema ....... ~I.-.:I [)ysllttp_ '"-_. 
EhWIOanIo •• yndmrne (EOS) 0<;1nI1IOtO. ~I Sjogren I Syn<llome 
8;o...oplldrc Fasalll OSI«>a ....... 1rhpe1'lel;1;> (Of) S)'3I8tnIC ltlPJI EryH,.r!\IlIOSUS (SlE) 
Ga'll Cal (l .... pof~ Mtv .. Po/)'_otts NocIoIa SV3I""'~ ScIerosrs 
Goo Po/vmyalgol R~"ca Wege~",'. G<1onoJomiOIOI" 
~v"' ....... PoIymyoI.bS & D&< ...... omyoo.r~. 
4 Un 01 mitdieines 10 l rell an Injury bela .. Or during partic:ip<>lion 
If you ilInswe'e(I YES to question 4 in sectIOn E ~ase COITIple1e the following twoquesuons rll3ted 10 
meOrc,ne lIU fa!' IlIjUne!I before or Qunng raees 
o Paraceta'T1Ol (e g Panado. Tytenol) 
(4a) WhICh of lIle folloW1ng o NIlI'I-$laroodalan\J.IIln.n.natOl'll'l (e,g, Vottaren. Catallam) 
medIClroeS haVfl you used ,II o CO<1lSORe ~I 
the past \0 treat an ' .... ury in o CO<1lS011e 1,...aIan 
Ihg WU~ 11111 !!:!lIar! a DCaden ... 
'~7 o AnlH'lllammatory gel~earnslpalelles 
D My _ patn k~l .... (Speofy I 
D Parooetamd Ie g Panado, Tyt~) 
f4tl) WI>rch of lhe 10Il0'wu1g 
o JIk)n·steroidal aoti-lf'I"ammalories leg Vollaren, Calaftam) o CO<1,sone (p~lsl 
med~ h ..... ~ou used ... o Cortisone injection 
It>e past 10 treal IIfI II'Ijll1'f 
<lunng I rae.? § Codeine 
Anti-innammalOry gailleraaml/patellas 
I Any olMe. pain killers (Spec.ily 
>0. 
, , , during exercise 
II )'0</ answered YES , S In seetiOO E pteMoe rnd!cate whICh gastro'~tcSl...,al 5ymplOm$ you 
have eyer SUlfered~ ';: ~; and. now ',eq:l!!n~1 (111 the last 12 mc",lhs ana In the lasl 10 
' IIOOS), 8~d In wh~ t 
Number oij,mes." Numoer of urnes 
Symptom Ine lalll 12 months .., \asIIO races Tick type olaureisa 
I , 
,[ " ~ NallSell J 
,', J , [~ 
Heartburn J, ,0" 
Abaommal pilln J_~~~~,p " '5 
Urgil to pass a 
&toolldelecale l o S-nm,"lI. 0 CyclIng. 0 Runnl,,!! 
O",.rhoea J, ,0, , ~ 
f'ass...,g tIIood In o Sw.nm,,'g. 0 Cycl,,'lg. 0 Running tile st~ 
6. Diseases of the nervous system 
II you answered YES 10 question' ,n sedlO'1 E !)!ease molCaiC ... "hd> I\IINOUI dISease Iym~ y<lu 
rave ever suffered from dUring BUfCi .. &"11 . how heqo..e!llty (in !he ~st 12 mot'tlhs "nil on tile Inl 10 
fIlCH) and In whICh type 01 e_efQle 
Numbe< Oft:mes m Number ot lImeS I 
Symptom the lasl12 months ,n IMI 10 raees Ti(:k tYlla of .... cln 
jdudng "'rs;!lel (d uring r,,~e!1 
,.,,,,,,"" o SWImmIng, 0 Cycling, 0 RLmnmg 
Nerve Unghng ,~ ! I 0 5,,,,,,,ml"ll, 0 Cye llng, D RuM"'" tile /lant15 
L~ of sensabon o S'Mmm."II . 0 C),(:lIng, o R~nnH\g on t/>e hands 
'" 
7. Genilililrilci i njury during cycling 
If you answered YES 10 quntJon 7 In sectlor1 E. please IndICate whd1 symptoms 01 geOlla l tr.IGt injury 
hilve )'00 suffered from during or ilfter cycling. how frequently (in the last 10 Se5SKHlS). how long 
symptoms last. and what ta~tors prevent ill relieve symptormi? 
Numbe. 01 
l imes In Plnse indicil" Plene Indic~te If any of the following .educe o r 
Symptom the lasl l0 when Ihe symptoms 
cycling occur 
p.evenllhe symptoms (c~n lick more Ihan onol 
sessions 
o Only during o Chilnging the saddle type [ronG 
DUling and up to o Chang n9 the saddle pos,tfon 
GeMal 1 hO~f aller cycl ,ng o Usong padded cychng shorts 
numbness o Duong and t-24 o Wearing no underwear 
hours after cyc l,ng o WearinQ add,t,o fl<ll underwear o DU"1lQ and ~ 24 o Dlher (S;>oc.ly· I 
hours ~ller cycllflQ 
o Only dutlng o Chang,ng Ihe saddle Iype cycltng o DlJflng and up 10 o Changing the saddle pos,tlon 
Genita l t hour alter c)~I,ng o Us'1lQ padded cycling slrorts ,om o Du~ng arld 1·24 o Wea"ng no underwear 
~ours after cycll "9 o Weanng add,lfonal underwear 
Q During and ~ 24 o Other (Spec,fy I 
hou,S OIlier cycling 
o Only dunng o Changong lhe saddle Iype 01'n9 
During arid up 10 8 Changing 1M saddle pOSItIOn 
Genital I hour afler Cldmg Us,ng padded c)'<.:llng shorls 
btlllSlfIg o During and '·24 o Wea"ng no ~nderwea r 
hours alter cycl ing o Wea"r19 add,lional underwear o During and ~ 24 o Other (Spl>Clfy I 
hours OIlier cycli"9 
Altered o Up to 1 hour after D ChanglMg the Saddle type 
se(~al [jl,ng o CMnglng the saddle pOSIMn 
f~1"ICton 1·24 hours after D Us,ng padded cycling shorts 
folloWIng a O ling o Weanng no underwear 
,~'" ,. 24 hOUrs attar D Weanng additional underwear 
Ses$1OfI cycling D Other (Specify I 
'" 
8. Allergy history 
If 1"'" answe,ed YES to question 8 on se<;hon E. ole"se complete Ine fo ll ow on g q~eshon5 (S" to !Ie) 
rejated to you, current and past hostOf)' of allergies 
, I , I ,.,,' 
(ab) Plene lick which ~I!e 2f alleal~ do you current ly suffe r from 
NOSlt (hay lever) YesDNoD S,nu 5>105 Yes D NoD 
~ 
YesDNoD 
Skm al lergoes YesDNoD Eye aUergoes Yes D No D , , Ye5DNo D 
A11e<gy to foods YesDNoD ::~ Yes 0 No D Om. 
(81:) Pleasa tick which Iype of alleray do you currentlv take medication lor 
Nose (hay level) YesDNoD S<I'1uS,M Ye~DNoD Yes D NoD 
~~, Sill" 8Ilerg0e5 YesDNoD Eye anergJe5 Ye5 D No D Yes D No D 
Anergy to loc.:js YosD No D 
",", 
Ye5 D NoD QlTler 
(lid) Ptease tick which type of medication do you currently take 
CDrtlsone nOSe YesDNoD 
Cortosone nose 
Ye5 D NoD 
A"-
YesDNoD spray ",hale' ~lTle 
Ant • .t1Lsiarrune ' ; 
Cort'sooe cream YesDNoD YesDNoD , YesDNoD 
c'eam 
(8e l Please lick which sYl!! ptoms 2! Iliergy do you currently suffe' from 
Snel!lon9 Yes 0 No D Itchy runny nose Yes D NoD Headxhe Yes D NoD , 
" ~ '~0"00 
, ~o , Blocke<:J now ,., J "0 0 ,0
~. Post r\ils<o l onp Y~s D No ~"' ~~ ~ ~O 
In wll.ch months olille yea' dO 
yuu ,"ur L!;!rb: Ir~." ~,rr ,,,!urr,, u[ OJan o Feb o M~<d> o Apnl O M~Y o June 
alle rgIes? (You tICk rnme than o July 0 Aug o Sept Do. D"~ DD~ 
~) 
(81) Please tIck which Iy!!! Qf aHe'9Y did you suffer from in the put (NOT cUflenUyl 
Nose (~"Y fever) Yes D No D Sinus1~s YesD No D 
~, 
I~"U", 
Sk'll at lergif!s Yes D No D Eye a ll ergies YesDNoD 1b"U"' , 
Allergy 10 foc.:js YesDNoD " ~-" YesDNo D 010. 
9, A,lhm, hl'lory 
ao.swered YES to qu .. Uon 9 >n section E plaase compklte the foHoWlflg quoShOn5 (9a 10 Ilk 
to your current history of astnma 
(9al Do you curren~y slllfer Irom ast~ma? YeS O No O 
19b) How fYlany years hBlle you lulfered from asthma? (ye.l ) 
I' ~~~_HOW WilS your asmma A oJuo,:ll,I! 14,It,y .. h ;"U,,, Y ~ "Il ~"" (UI"'''~ ~" \I .... "I".lIl\In 
Illilgrosod' Lung function lest (blow test) but no e.etCl1Ie 
Lung funetion test (blow tell) belOle and aft'" e~e<c_ 
MelaCholine chall9nge test 
Eucapnlc It l'Per~entllatll)t1 test (rebreath,"9 tell) 
Other lest (SpecIfy ) 
I,,,,,, 
;.~ 
Asthma tha i QCOJrs al any tome but no\ OutlnQ exCfc,,, 
I ~? Astllma tIlal OCClJr$ at any lime "'cIo0'"9 Ounng e.ere'WI 
' ~ 
(!Ito) Please ,~alCilte how 
[] '" 2 ' week 0 2-4 l -....IOOk 0 >4 / week f,equently do you o All the tlfTMl 
currenlly uperience the Nig1>t lime symptoms (per month ) 
aymptom5 of asthma 
O"- t l monlh 0 2-3 { month o ! 4 / month o 14 !he Ior'oe (shortness of IXe<lth 
wheezm", CO\lgnlng or e. ercise rela ted symptoms (par 10 a. a,clsa sessions) 
coughing altO!' e ~ercose)' 0"-1 per 10 s.e5SlOTtS 02.3 po. 10 SesSIOns D,?:4 per 10 sesSIOns 
(9f) Piease 100 ca!e If YOll D Na Itospo:ai adm:SSlon for itS!hma In the last 12 months 
had symP!oms 01 asthma 
tflaT wera $(I~ere &nOugh to o 1·2 hOSp1til1 a\lmlSSl()nS for astnma In the IaSl 12 mon!nS 
ne<;e$$,lato hospital 03-4 hospItal aom,ssoons for asthma ,n "'e las! 12 months 
~tlmi .. ion In Ihll lnl12 - ,,. 0>4 hosp,tal ildmlSS,ons far asthma In !he IaSI 12 months 
j9g1 MocIt tympt0!!!l of o Shortness of t>roath 
nthrnl do)'Ou cu'rently , 
suffer lrom? ~ ) 
(9h1 What medication do I 0 ConiSO<le inhaler (e 9 Becla16, 8ec1010r1e, Becodisks, 8ecot lde. 
you cunan!!y use for your Budeflam, FI!l(onde, InflammW:ta. Pu lmicor1, Ovar, etc) 
ast~ma? (YOll may !JCk more o Salbutamol (broncMd~a\or) inhaler (e.g. Ventol in, Venleze, Voma>:, 
11""", one option) Airomif. Astha\llnt etc.) 
o Salmeterol (broochodilatOf) iIlhaler (Sarevent) 
o Fenote<ol {brorchO<l~ator) I"!later (Sa.-Olec) 
o T ert>ulaline (bronchodilalOr) Inhaler [Brocanyt) 
o Formolerol (bronchod ilator) ",ha lf!( (e g. Foradil. Forme<:, OXts) 
n tpretrOPtUm (brl)lld)od,ator) inhelM (Alroven1) 
o Tiotroplum (brcnchod~alor) inhalar (Sptrtva) o Combined cortisone and bronchod ilator inhaler (e g. Alrovent 
Beroduat, Corrbtvenl, Duotin, Duovenl, Serelide, SyrnbtCQrd) 
CorUsone tablets 
BroocMclilalor tablets 
Leukolnene receptor anlagooist tablets (e 9 Ac:ccolate, Singulaif) 
Other Inhalf!( 
Q1her medicatlOl1 I 
(9i) When do ~ou use ygur o Daily (irrespectlva 01 exercise) D Only before &xercile 
medication for your D Other (Specify: I asthma? 
'~" m" 
asthma? 
(9k) Have you obtained TUE (therapeutic use utmplion forms ) lor your as:hma 
YesO NoO medICatIOn? 
'" 
10. Hist ory of previous collapse 
If yuu ....,s_rOO YES 10 question 10 I~ sectlO~ E please complete the fol lowing questOOn5 ( lOa " tOd I related!(l yuur c~rren( MistOf"j 01 asthma 
o Tr"a.ni~g 
(1 Cal H"ve you collapsed dunng framing or 'ac,ng? B Rac",g 
Tra.n 'ng and rac ing 
(lOb) How m,,,,y ~me~ Mve yo~ col l~p""d In ,,,.,n'ng ~"S~'<>rl -- training s",,~1I')n 
<lI 'aces dOling too laS! five ~e .. r!7 races 
(10e) When you col lapse does It mostly occur befofl! of "fter o BMore the flmsh 
the finISh I,ne I completion of tMe tra.n,ng sess on? o Aller tne finish 
o Dehydration o Heat III~ess 
(IOd) Wnat IS rhe cause of you o HyponatIemla 
coflilpse? o Low I>lood pressure o Low blood sugar o Othe' col\dillOn (Sp~'C,fy I 
'" 
~ 
11 . Hislory of any currenl lnjury Ihal you s uffer from 
If yO<J ansWl!led YES to question 11 on seClIOl1 E please complete the following questl(ms (11a to 119) 
r~\ed to each Or your W llent mJurylies (S~e IS prov'ded for two 'llJOlles) 
Injury 1 
Ilia) What was the approximate dale when yo.u fnst became awarll 01 
Mooth 'M' the InJUry? 
(li b) Pleas.e Indicate wludl side 01 your body IS Injured (,1 applicab le) o Right o l eft 
o Hea<! o Elbow o HamstIllg 
O N'" o Forearm o Qua<!riceps o Face O wnst o Knee 
(111::) Please II'Id,cate whICh analomi<;aj area o Froot chest o Finger o Shin 
is currenUy injured o Back chest o lower back 0 Ach~11IS o Shoulder o Hlp B Ankie o Upper arm o Th igh '00' 
Other {Specofy: I 
o Muscle o ligament 
{\ IdJ Please ond lca te Ille type of SII1lCUlre o T endCf1 o JOOl1. 
that was "'IUfed o Bonll 
Other {Specofy· I 
o Runmng o Cydlng 
(i te) Please ,nrncaie In which wort o Swtmm OlIl (dISCIpl ine ) thII "'Jury occurred 
Other {Specily· I 
(1 1f) Please,ndlCilte 
I ~ I only experience s~Ptoms after exercise - Gr9de I o 1 expllrience s~ptoms dumg eXefcose. but it d<>es nOi interfere with exercme 
!he seventy of the • Grade 2 
InjUry (tock one box o 1 experience symptoms dunrtllexercise thai may interfere with my tramillgi 
please) competrtion· Grade 3 
I  n "I am so pa,nfu l that 1 may not be able 10 \lain or compete · Grade 4 
o Rest o Tablets o Stretches o COft,sone Injed,OIl 
(1 1 9) Please Indicate how you r Injury was o Physiotherapy o Other Injection 
trealed to date (you can ~c:k more than o Surgery o Orthotics 
~I' B Sirengthenl!tg eXllfcises 
EqUipment change 
Other (Spec"y I 
I ,2 
\' la) WI\;It ""$ tt>e approx,maU! date wnen you first became ....... re 01 MOI1lh Yeer 
Ihe IIIl"ry? 
.~ 
~ t 1 b) , , i lOM , He .. 
""'" >~ B::' " te) P~8So1 IOd0C3te WhICh incllOl'T'llC<l1 iffea Front chest 
"(:I.o'renllv injUred Back chest ''''' I !~. cl~~· Uppwarm "'. 
Muscle OUgament 
It Td) Pleasa IflOlCale the type QI 51l'ucture 
l~doo DJoinl lllal V1i15 irljured 
I 
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